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ABSTRACT 
Investigation of the quantitative relationship between circulating 
placental mRNA and fetal growth 
Submitted by PANG Weng I for thesis submitted for the degree of Master of 
Philosophy in Chemical Pathology at The Chinese University of Hong Kong in June 
2008 
Fetal growth monitoring is critically important in prenatal care and the assessment of 
fetal well-being. Intrauterine growth restriction (lUGR) accounts for a substantial 
proportion of fetal morbidity and mortality, as well as chronic diseases. Due to the 
suboptimal diagnostic sensitivity of current modalities to evaluate fetal growth (e.g. 
ultrasonographic measurements of fetal biometric parameters and maternal serum 
biomarkers), there is still much room for the further exploration of a more refined 
and objective approach for fetal growth assessment. 
The discovery of the presence of placenta-derived fetal RNA in maternal plasma has 
opened up new possibilities for noninvasive prenatal investigation. Previously, 
placental transcripts detectable in maternal plasma have been systematically 
identified by microarray analysis. In this thesis, I targeted fetal RNA species in 
maternal plasma which are functionally related to fetal/placental growth and 
investigated if their maternal plasma concentrations correlated with growth of the 
pregnancy. 
In the first part of this thesis, growth-related placental transcripts, namely chorionic 
somatomammotropin 1 {human placental lactogen) (CSHl), growth hormone 2 
i 
{placental growth hormone) {GH2), KiSS-1 metastasis-suppressor (KISSl) and a 
disintegrin and metallopeptidase domain 12 {ADAM 12), were validated to be 
pregnancy-specific and detectable in all three trimesters of pregnancy, using one-step 
real-time quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR). 
CSHl, GH2 and ADAM 12 mRNA were selected as potential growth markers 
because they were shown to possess positive gestational trends throughout 
pregnancy along with positive fetal growth. 
The second part of this thesis demonstrated the relationship between the maternal 
plasma mRNA concentrations with birth and placental weight and fetal growth 
parameters from pregnancies with a range of customized birth weight centiles. 
Remarkably, the concentration of maternal plasma GH2 significantly correlated with 
birth weight and a number of fetal biometric measurements estimated by ultrasound 
scans. 
Finally, the clinical utility of the target transcripts was explored by cross-sectional 
and longitudinal comparisons of the maternal plasma mRNA concentrations between 
pregnancies complicated with lUGR associated with or without preeclampsia (PET) 
and gestational age matched controls. Aberrantly higher concentrations of maternal 
plasma ADAM 12 mRNA was observed in lUGR with PET than normal pregnancies 
in the cross-sectional comparison. There was no significant difference for all markers 
between lUGR without PET and controls in both the cross-sectional and longitudinal 
comparisons. 
This thesis addresses for the first time the potential use of circulating fetal RNA to 
investigate lUGR. I have developed a novel strategy in identifying surrogate markers 
ii 
for the study of fetal growth. This strategy may also be potentially useful for the 
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SECTION I : BACKGROUND 
1 
Circulating nucleic acids in prenatal diagnosis 
CHAPTER 1: Circulating nucleic acids in prenatal diagnosis 
1.1 Prenatal diagnosis 
Prenatal diagnosis is now a routine part of obstetrics practice. Conventional invasive 
methods of obtaining fetal genetic material for testing, such as chorionic villus 
sampling and amniocentesis, pose a finite risk to the fetus and contribute to increased 
fetal loss rate (Mujezinovic and Alflrevic, 2007). As a result, it has been a 
longstanding quest to develop safer tests for prenatal assessment. One attempt for 
noninvasive analysis of fetal genetic traits was by the isolation of fetal nucleated 
cells in maternal blood (Bianchi et al.’ 1990). However, the rarity of such fetal cells 
in maternal circulation and persistence between pregnancies (Bianchi et al.’ 1996) 
have greatly hampered their robust use in noninvasive prenatal diagnosis (Bianchi et 
a/., 2002). 
In 1997，Lo et al made a pivotal breakthrough in medical genetics by describing the 
positive detection of Y chromosome-specific DNA sequences in the plasma of 
pregnant women carrying male fetuses (Lo et al.’ 1997). A few years later, the 
existence of fetal RNA in maternal plasma was reported (Poon et al, 2000). More 
recently, placenta-derived microRNA (miRNA) was also found to be detectable in 
maternal circulation (Chim et al., 2008). The discovery of circulating fetal nucleic 
acids has opened up new opportunities in noninvasive prenatal diagnosis and this 
field has developed rapidly over the last decade. 
1.2 Circulating fetal DNA in maternal plasma 
1.2.1 Biology of circulating fetal DNA 
2 
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Recognizing the "pseudomalignant" nature of the human placenta (Strickland and 
Richards, 1992)，Lo et al discovered the presence of cell-free fetal DNA in maternal 
plasma/serum (Lo et al., 1997) following the report of the presence of tumor-derived 
DNA in human plasma (Chen et al, 1996; Nawroz et al., 1996). Fetal DNA could be 
readily detected as early as the fifth week of gestation (Honda et al., 2002) and even 
at 18 days postembryo transfer in the circulation of women undergoing assisted 
reproduction (Guibert et al, 2003). Rapid post-partum clearance with an apparent 
half-life of 16.3 min (Lo et al, 1999c) ensured that fetal DNA do not persist after 
pregnancy (Johnson-Hopson and Artlett, 2002; Smid et al.’ 2003). Circulating fetal 
DNA constitutes a mean percentage of 3.4 - 6.2% of total plasma DNA (Lo et al., 
1998b), mainly in the form of short DNA fragments (Chan et al” 2004). 
Although the placenta, fetal hematopoietic cells, and the fetus itself have been 
suggested as candidates of the origin of circulating fetal DNA (Bianchi, 2004), 
many studies support the placenta as the major source. For example, the existence of 
fetal DNA in maternal plasma before the establishment of the feto-placental 
circulation (Guibert et al, 2003), the detection of maternal plasma placental DNA in 
cases with confined placental mosaicism (Masuzaki et al.’ 2004), the absence of SRY 
sequence in both maternal serum and cytotrophoblast in spite of male genitalia 
revealed by ultrasound in a case with 45,X karyotype in trophoblast analysis (Flori et 
al.’ 2004), the presence of placental epigenetic signature in maternal plasma DNA 
(Chim et al., 2005), and the detection of fetal DNA in anembryonic pregnancies 
(Alberry et al.’ 2007). It is believed fetal DNA is released into the maternal 
circulation by necrosis and/or apoptosis (Tjoa et al., 2006a). 
1.2.2 Clinical applications of circulating fetal DNA 
3 
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Circulating fetal DNA in maternal plasma holds great promises for noninvasive 
prenatal diagnosis or monitoring (Lo and Chiu，2007). These applications involve 1) 
qualitative detection of fetal-specific sequence in maternal plasma or 2) 
quantification of plasma fetal DNA concentration and then comparison with 
gestational age-matched normal pregnancies. 
1.2.2.1 Qualitative fetal-specific sequence detection 
Nowadays, prenatal determination of rhesus D (RhD) status (Lo et al.’ 1998a; Costa 
et al., 2002) and fetal gender for prenatal diagnosis of X-linked disorders and 
congenital adrenal hyperplasia (Rijnders et al., 2001; Chiu et al.’ 2002a) using cell 
free fetal DNA are available as routine clinical practice in several European centers 
(Hahn and Holzgreve, 2002b; Finning et al.’ 2004). The noninvasive RhD blood 
group testing has been lately approved in the United States (Sequenom Inc., 2007). 
Besides, prenatal diagnosis of paternally-inherited mutations with circulating fetal 
DNA was successfully achieved. For example, by positive detection of autosomal 
dominant diseases, such as achondroplasia (Saito et al.’ 2000)，myotonic dystrophy 
(Amicucci et al, 2000) and Huntington disease (Gonzalez-Gonzalez et al.’ 2003); 
and by exclusion of autosomal recessive diseases, including congenital adrenal 
hyperplasia (Chiu et al, 2002a), p-thalassemia (Chiu et al,, 2002b; Ding et al,’ 2004; 
Li et al.’ 2005), cystic fibrosis (Gonzalez-Gonzalez et al, 2002) and hemoglobin E 
(Fucharoen et al, 2003; Tsang et aL, 2007). 
1.2.2.2 Quantitative aberration detection 
Using real-time quantitative polymerase chain reaction (QPCR) assays, aberrant 
concentrations of plasma fetal DNA has been observed in a number of pregnancy 
4 
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complications and fetal abnormalities, e.g. chromosomal aneuploidies (Lo et al., 
1999a; Zhong et al., 2000a; Wataganara et al, 2003), preeclampsia (PET) (Lo et al.， 
1999b; Hahn and Holzgreve, 2002a), polyhydramnios (Zhong et al.’ 2000b), 
fetomatemal hemorrhage (Lau et al, 2000; Samura et al, 2003)，hyperemesis 
gravidarum (Sekizawa et al., 2001), invasive placentation (Sekizawa et al., 2002), 
intrauterine growth restriction (lUGR) (Caramelli et al.’ 2003), preterm delivery 
(Leung et al.’ 1998; Farina et al.’ 2005) and ectopic pregnancies (Lazar et al” 2006). 
Among these, particular research interest has been focused on detecting PET and 
fetal aneuploidies. Several studies reported increased levels of circulatory fetal DNA 
in preeclamptic relative to normal pregnant women (Lo et al.’ 1999b; Smid et al., 
2001; Shimada et al, 2004; Zhong et al., 2004). Such elevation could be seen prior 
to the onset of disease symptoms (Leung et al.’ 2001b; Zhong et al., 2001a, 2002) 
and corresponded to the severity of the disorder (Zhong et al.’ 2001b). In the case of 
fetal aneuploidy detection, quantitative aberrations of circulating fetal DNA have 
been found in trisomy (T) 21 (Lo et al” 1999a; Zhong et al, 2000a; Lee et al, 2002) 
and T13 (Wataganara et al, 2003)，but not in T18 (Zhong et al,’ 2000a; Wataganara 
et al, 2003). It is of interest that fetal DNA can modestly increase the screening 
performance of Down syndrome in the second trimester when analyzed with the 
currently available quadruple serum biochemical markers (Farina et al” 2003). 
1.2.3 Circulating fetal epigenetic markers 
Most quantitative analyses of maternal plasma DNA rely on the detection of Y 
chromosome markers, which is only applicable to male fetuses. Moreover, it is 
technically challenging to identify a maternally-inherited fetal allele from the 
preponderance of maternal background DNA. These constraints can be overcome by 
5 
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the enrichment of fetal DNA prior to analysis (Lo and Chiu, 2008) or using fetal 
epigenetic markers (Lo, 2006). By analyzing the differential methylation pattern 
between the fetus or the placenta and the mother, universal fetal epigenetic markers 
in maternal plasma, such as hypermethylated RASSFIA and hypomethylated 
SERPINB5, have been shown to be useful in prenatal RhD genotyping (Chan et al., 
2006) and the assessment of T18 and PET (Chim et al.’ 2005; Tong et al, 2006; Tsui 
et al, 2007). 
1.3 Circulating fetal RNA in maternal plasma 
1.3.1 Biology of circulating fetal RNA 
Circulating fetal RNA in maternal plasma represents another type of universal 
marker for noninvasive prenatal diagnosis. Poon et al, demonstrated for the first time 
the presence of fetal-derived, Y-chromosome-specific zinc finger protein (ZFY) 
mRNA in maternal plasma (Poon et al., 2000). The detection of cell-free RNA 
species is rather unexpected, in view of the well-known liability of RNA. The 
surprising stability of circulating RNA has been attributed to their association with 
subcellular particles (Ng et al., 2002) suggested to be apoptotic bodies (Hasselmann 
et al.’ 2001) or syncytiotrophoblast microparticles (Gupta et al, 2004), which might 
protect them from degradation (Tsui et al, 2002). Fetal RNA exists in the maternal 
plasma with a preponderance of 5' mRNA fragments (Wong et al., 2005), 
implicating that they are partially degraded and so higher detection sensitivity can be 
achieved if quantitative assays are designed towards the more abundant 5' end of 
mRNA. Recently, Rusterholz et al. showed with an in vitro model that oxidative 
stress could reduce the levels of full-length, microparticle-coupled 
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glyceraldehyde-3-phosphate dehydrogenase {GAPDH) mRNA transcripts released 
by the placenta (Rusterholz et al.’ 2007). This study has offered insights that 
qualitative analysis of placental mRNA integrity might be useful to diagnose 
disorders of altered placental oxidative stress, e.g. PET (Rusterholz et al., 2007). 
Successful detection of placenta-derived mRNA species in maternal plasma, such as 
chorionic somatomammotropin hormone 1 {human placental lactogen) {CSHl, alias 
liPL), the beta subunit mRNA of human chorionic gonadotropin {J3-hCG) and 
corticotrophin-releasitig hormone (CRH), suggests placenta as the predominant 
source of circulating fetal RNA (Ng et al., 2003a; Ng et al., 2003b). A unidirectional 
transfer of placental RNA from the placenta to the maternal circulation was also 
demonstrated (Ng et al, 2003b). Since then, more circulating placental transcripts 
have been reported. Oudejans et al and Go et al. respectively detected a panel of 
chromosome 21-encoded mRNA sequences of placental origin (Oudejans et al.’ 
2003) and placental transcription factor mRNA (Go et al.’ 2004) in maternal plasma. 
Furthermore, the establishment of a systematic approach to study placental gene 
expression by microarray analysis has generated an extensive list of placental 
transcripts that could be detected in maternal plasma and developed as novel plasma 
RNA markers (Tsui et al., 2004). 
Circulating placental mRNA can be readily detected as early as the fourth gestational 
week and is cleared rapidly after delivery with a median clearance half-life of 14.1 
min (Chiu et al.’ 2006). In contrast to plasma fetal DNA, which increases 
proportionately as gestation progresses (Lo et al., 1998b), placental mRNA levels in 
maternal plasma correlate with the variation of the corresponding protein product 
levels (Ng et al., 2003b; Ge et al, 2005) or the placental expression profile of the 
7 
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corresponding genes (Tsui et ai, 2004). mRNA levels were not altered even after 
invasive procedure like laser ablation of placental-shared vessels in twin-to-twin 
transfusion (Tjoa et al., 2006b). 
1.3.2 Clinical applications of circulating fetal RNA 
Circulatory plasma RNA has certain advantages over cell-free fetal DNA assessment 
in clinical use because it can be applied to all pregnant women as gender- and 
polymorphism-independent fetal-specific targets, and most importantly, 
disease-specific gene expression patterns can be exploited for marker development 
(Tsui et al, 2004). 
1.3.2.1 Quantitative aberration detection 
Quantitative aberrations of placental mRNA transcripts has been demonstrated in 
various abnormal pregnancies, such as Ci?//mRNA in PET (Ng et al.’ 2003a; Zhong 
et al., 2005a; Zhong et al., 2006) and preterm delivery (Zhong et al., 2005b), and 
p-hCG mRNA in gestational trophoblastic disease (Masuzaki et al” 2005). 
Particularly in the study of PET, CRH mRNA has been noted to increase by 
10.5-fold in the plasma of preeclamptic women (Ng et al, 2003a), positively related 
to disease severity (Farina et al.’ 2004) and may be with more pronounced elevation 
in early-onset PET (Zhong et al, 2005a). Recently, a panel of 7 novel mRNA 
markers, namely vascular endothelial growth factor (VEGF), VEGF receptor-1, 
endoglin, placenta specific-1, selectin-P, plasminogen activator inhibitor-1 and 
tissue-type plasminogen activator have arisen for the prenatal assessment of PET 
(Purwosunu et al.’ 2007a; Purwosunu et al,, 2007b; Purwosunu et al., 2008; 
Sekizawa et al.’ 2008). They were reported to be able to predict PET occurrence due 
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to the observed significant elevation of these markers in asymptomatic pregnant 
women who subsequently developed PET (Sekizawa et al.’ 2008). C/?//mRNA was 
shown not useful in PET prediction in early second trimester (Sekizawa et al., 2008). 
Together, these studies illustrate the potential use of the quantification of placental 
mRNAs in maternal plasma to monitor placental pathologies. 
1.3.2.2 Chromosomal aneuploidv detection 
Ng et al. have preliminarily investigated the application of circulatory placental 
mRNA in detecting fetal chromosomal aneuploidy (Ng et al.’ 2004). They showed 
that p-hCG mRNA concentration was significantly reduced by 9.4-fold in T18 
pregnancies and mildly elevated by 2.2-fold in T21 pregnancies (Ng et al.’ 2004). 
The presence of placenta-derived mRNAs located on chromosome 21 in 
first-trimester maternal plasma suggested potentials for early prenatal Down 
syndrome screening (Oudejans et al.’ 2003). 
Last year, Lo et al made another breakthrough by demonstrating the feasibility of 
noninvasive chromosomal aneuploidy detection (Lo et al” 2007b). They utilized 
mass spectrometry to analyze the allelic ratio of a single nucleotide polymorphism 
(SNP) on placenta-specific 4 {PLAC4) mRNA, a placenta-expressed transcript on 
chromosome 21 (Lo et al., 2007b). By comparing the SNP ratios between euploid 
and trisomic pregnancies, T21 was detected with a sensitivity of 90% and a 
specificity of 96% (Lo et al, 2007b). Nonetheless, this approach is dependent on the 
heterozygous rate of the target SNP locus (45% of the total population for the 
reported PL AC4 SNP), which may be infrequent. Hence, in a more recent study, Lo 
et al successfully developed a nonpolymorphism-based method for the noninvasive 
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prenatal detection of T21 with high precision by digital PGR (Lo et al., 2007a). This 
method, known as digital relative chromosome dosage (RCD), evaluates any 
overrepresentation of chromosome 21 with respect to a reference chromosome by 
direct counting of the total copy number of DNA originating from chromosome 21 in 
one or more 384-well PGR plates (Lo et al.’ 2007a). 
1.3.3 Enrichment of fetal RNA 
Despite the attractiveness brought by circulating placental mRNA as markers for 
noninvasive prenatal investigation irrespective of fetal gender and polymorphism 
status (Lo and Chiu, 2007), such RNA species are present in the maternal plasma at 
limited amount. To enrich this invaluable source of fetal genetic material, several 
enrichment protocols have been explored. For example, adding more TRIzol LS 
during blood processing or using gentle centrifligation protocols for plasma RNA 
extraction significantly increased the yield of fetal RNA in maternal plasma (Heung 
et al., 2008). Enrichment of fetal RNA may enhance the accuracy and reliability of 
detecting fetal RNA in maternal plasma, especially for those marginally detectable 
transcripts. Another way is to increase the amount of total RNA with commercially 
available RNA pre-amplification kits prior to quantification analysis (Lo et al., 
unpublished data). 
1.4 Circulating microRNA in maternal plasma 
Very recently, a new class of circulating nucleic acids in maternal plasma has been 
characterized, namely placenta-derived miRNA (Chim et al” 2008). miRNAs are a 
family of small (21-25 nucleotides), non-coding RNAs that negatively regulate gene 
expression at the post-transcriptional level (Lai, 2002; Bartel, 2004). Based on the 
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hypothesis that miRNAs of placental origin might be released into maternal 
circulation like placental RNA, Chim et al. have demonstrated the presence of 
pregnancy-associated, placenta-derived miRNA in maternal plasma at high 
concentration and stability (Chim et al.’ 2008). With further investigations, it is 
hopeful that this novel class of molecular markers will be practical in pregnancy 
monitoring. 
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CHAPTER 2: Fetal Growth and Weil-Being 
2.1 Normal fetal growth 
Fetal growth is a complex process controlled by numerous interactive factors of fetal, 
maternal, and placental origin. Figure 2.1 briefly summarizes the dynamic 
interactions between the fetus, mother and placenta, which are described below. 
2.1.1 Role of the mother 
Maternal factors, particularly height (Bryan and Hindmarsh, 2006), and the uterine 
environment (Brooks et al., 1995) has a significant influence on fetal growth. Factors 
like health, hypoxia, smoking and nutritional status of the mother affect maternal 
development during pregnancy. Maternal adaptations to pregnancy, regulated by 
placental hormones, include increased uterine blood flow to meet the demands of the 
growing uterus, fetus and the placenta (Kliman, 2000), altered maternal metabolism 
and behavior, and increased nutrient intake for adequate provision of essential 
nutrients and oxygen to the fetus via the placenta (Bauer et al., 1998). These changes 
in turn promote placental development and fetal growth. On the other hand, several 
maternal constraints like limited uterine capacity or nutrients supply restrict fetal 
growth (Gluckman and Pinal, 2002). 
2.1.2 Role of the placenta 
The placenta maintains fetal homoeostasis and is the site of nutrient and waste 
transfer between mother and fetus (Bauer et al., 1998). During early pregnancy, 
extravillous cytotrophoblasts differentiated from trophoblast cells invade the uterus 
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and spiral arteries, which are transformed into large vessels of low resistance (Lyall 
et al., 2001) to facilitate increased uteroplacental blood flow (Kliman, 2000). This 
promotes placental growth and synthesis of growth-regulating hormones (e.g. 
insulin-like growth factors (IGFs) and glucocorticoids) and substrate-transporters. 
The placenta also sets a glucocorticoid barrier limiting the free transfer of Cortisol 
between the mother and the fetus (Benediktsson et al, 1997). 
2.1.3 Role of the fetus 
The fetal genome is the major determinant of growth at early fetal life. Imprinted 
genes are genes predominantly expressed from one of the two parental chromosomes 
and have key roles in placental/fetal development and growth (Fowden et al., 2006). 
The fetus signals the placenta to enhance maternal nutrient transfer via placental 
growth, transporter activation and placental hormones synthesis that can influence 
maternal metabolism. 
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Figure 2.1 Interactions between the fetus, placenta, and mother during 
pregnancy. Maternal constraint limits fetal growth, while maternal pregnancy state 
promotes placental growth, thereby promotes fetal growth. The fetus communicates 
with the mother via the placenta. (Adapted from Murphy et al,, 2006) 
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2.1.4 Role of the somatotrophic axis 
Endocrine factors are important determinants of fetal growth. Of these, the 
somatotrophic axis (IGF-system) plays a pivotal role in regulating fetal and placental 
growth, as demonstrated by many gene knockout and mutagenesis studies (Liu et al.， 
1993; Ludwig et al., 1996; Constancia et al.’ 2002). IGF-I and IGF-II (IGFs) are 
small polypeptides similar to insulin, which exert their effects via the IGF-I receptor 
and results in mitogenesis, prevention of apoptosis and cell differentiation. IGF-II is 
the major growth factor during embryonic development, then later in gestation, IGF-I 
becomes the dominant fetal growth factor and has been reported to be positively 
correlated to birth weight (Ross et al, 1996; Ong et al, 2000). In the circulation, 
only less than 1% of the IGFs are in the bioactive, free form; while the others are 
bound to one of the six identified IGF binding proteins (IGFBPs) with different 
affinities (Denley et al., 2005). These carrier proteins stabilize the IGFs, transport 
them to target cells, but also antagonize their binding to IGF receptors. 
Fragmentation of IGFBPs by specific proteases increases the bioavailability of IGFs 
to bind to IGF receptors (Bunn and Fowlkes, 2003). The IGF-II receptor, mainly 
responsible for IGF-II clearance, acts as a growth inhibitory component of the IGF 
system and also helps to transport lysosomal enzymes between intracellular 
compartments. 
2.2 Abnormal fetal growth 
Aberration of fetal growth occurs when the fetus is pathologically too small (lUGR) 
or too large (macrosomia). Both of which results in increased short- and long-term 
adverse sequelae (Lemer, 2004). The focus of this thesis will be on the former. 
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2.2.1 Intrauterine growth restriction 
In the 1960s, Lubchenco et al. made landmark observations on intrauterine growth 
(Lubchenco et al.’ 1963) which had prompted obstetricians and pediatricians to 
recognize a group of infants who had failed to achieve their genetically-determined 
fetal growth potential, named lUGR. lUGR is a common and complex obstetric 
problem that affects as many as 5-10% of all pregnancies in developed countries and 
6-30% in the developing world (de Onis et al., 1998; Galan et al.’ 2002). The growth 
restriction has significant impact on mortality and morbidity at all stages of life. In 
perinatal life, fetuses suffering from lUGR are at increased risk of stillbirth, neonatal 
mortality, prematurity, birth hypoxia, hypoglycaemia, hypothermia and infection 
(Mclntire et al.’ 1999; Vrachnis et al.’ 2006). In childhood, they are linked to poor 
growth and impaired neurodevelopment (Roth et al., 1999; Leitner et al, 2007). 
Eventually in adulthood, they are associated with increased rates of coronary heart 
disease, stroke, hypertension and type 2 diabetes (Barker, 2006). 
2.2.2 Definition of lUGR 
At present, there is still no definitive consensus on a particular cutoff percentile to 
classify a fetus as being growth restricted. The Royal College of Obstetricians and 
Gynaecologists has acknowledged several thresholds that are used to define lUGR, 
including 2.5出，3'�5山，10出，and 25化 centiles and 1.0，1.5 or 2.0 standard 
deviations below the population average (Royal College of Obstetricians and 
Gynaecologists, 2002). The most commonly used definition is fetal weight below the 
lOth centile for gestational age, which better describes small-for-gestational-age 
(SGA) infants. However, it is important to note that under this threshold, 
16 
Fetal growth and well-being 
approximately 70% of fetuses are healthy but constitutionally small rather than 
growth restricted (Ott, 1988). On the other hand, abnormal growth may occur with a 
"normal" birth weight that is less than the potential birth weight (Chard et al., 1992). 
The introduction of customized fetal growth standards has reduced the rates of 
false-positive and false-negative identification of lUGR (Gardosi et al.’ 1995; 
Mongelli and Gardosi, 1996; De Jong et al.’ 2000; Pang et al.’ 2000; Figueras et al., 
2007). Adjusted for physiologic variables like maternal height, weight, parity, ethnic 
group and fetal gender, customized birth weight standard is more suitable for a 
heterogeneous population. There is increasing evidence that customized birth weight 
standards, when compared to current population-based ones, improve the distinction 
between genetically small and growth-restricted fetuses in different populations 
(Pang et al.’ 2000; Ego et al, 2006). 
2.2.3 Risk factors of lUGR 
lUGR is a manifestation of various possible fetal and maternal disorders rather than a 
specific disease entity by itself. Since normal growth is dependent on intrinsic 
(genetics) and extrinsic (maternal and placental) factors (Bryan and Hindmarsh, 
2006)，any aberration of fetal growth has a multifactorial basis in terms of 
pathogenesis. Although the pathophysiology of lUGR is poorly understood, 
researchers have identified several risk factors associated with lUGR as depicted in 
Table 2.1 (Bryan and Hindmarsh, 2006). Among these etiologic factors, one-third of 
the variations of birth weight are determined by genetic factors, while two-thirds by 
environmental ones (Wollmann, 1998). Placental ischemia has recently been 
recognized as the most common cause of lUGR (Ananth et al, 2007; Kinzler and 
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Vintzileos, 2008). Symmetric lUGR, characterized by proportional small size, is 
believed to be the consequence of early intrinsic insults, such as intrauterine 
infection, chromosomal abnormality and congenital malformations, which affect cell 
division (Lemer, 2004). In contrast, asymmetric lUGR, characterized by 
disproportionately small body but normal head size, is considered to be the result of 
late extrinsic insults, like placental insufficiency and inadequate nutrient transfer, 
which affect cell growth (Lemer, 2004). 
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Table 2.1 Risk factors associated with intrauterine growth restriction. (Adapted 
from Bryan and Hindmarsh, 2006) 
Medical complications 
Preeclampsia 
Acute or chronic hypertension 
Antepartum hemorrhage 
Severe chronic disease 
Severe chronic infections 




Abnormalities of the uterus 
Uterine fibroids 
Maternal social conditions 
Malnutrition 
Low pregnancy body mass index 
Low maternal weight gain 
Delivery at age <16 or >35 years 














Abnormalities of the placenta 
Reduced blood flow 
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2.2.4 Diagnosis o f lUGR 
Monitoring the wellbeing and growth of the fetus is a major purpose of antenatal 
care. The early identification of lUGR is critical in order to establish antenatal 
surveillance to define the best time of delivery (Alberry and Soothill, 2007). The 
diagnosis of lUGR should begin with evaluating patients with significant risk for 
delivering a growth-restricted fetus (refer to Table 2.1) (Bryan and Hindmarsh, 
2006). Because of its multifactorial heterogeneous pathology (Wollmann, 1998)，it is 
difficult or even impossible to detect lUGR precisely with a single test. At present, 
various tests of assessing fetal growth and well-being have been explored and/or are 
available in clinical practice. They can be categorized into biometric, biophysical and 
biochemical tests. 
2.2.4.1 Biometric tests 
Performed routinely in clinical units, ultrasound evaluation of the fetus is the 
well-accepted standard for fetal growth monitoring. Ultrasound biometric tests are 
designed to predict fetal size and growth, if performed serially. In any evaluation of 
fetal growth, accurate gestational dating is extremely important as fetal growth 
patterns at different stages are compared to the expected value of the corresponding 
gestational age. Pregnancy dating determined by early ultrasound biometry of 
crown-rump length and biparietal diameter (BPD) (less than 28 weeks) is more 
precise than menstrual histories (Ott, 2006; Lynch and Zhang, 2007). If early 
ultrasound dating is unavailable, fetal transcerebellar diameter measurement will be a 
reliable predictor of gestational age in the third trimester (Chavez et al., 2004). 
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The most frequently assessed biometric parameters to evaluate fetal size are 
abdominal circumference (AC) (reflecting fetal nutritional status), femur length (FL) 
(reflecting fetal length), BPD and head circumference (HC) (reflecting fetal brain). 
Their measurements are compared to population-based nomograms of fetal biometry 
to screen for any deviation from normal fetal growth at particular gestational age. 
Estimated fetal weight can be calculated by combining fetal biometric measurements 
in a formula, always by the Shepard and Hadlock formulas (Shepard et al., 1982; 
Hadlock et al.’ 1985). Of all these ultrasound derived measurements, lUGR can be 
most accurately predicted when both AC and estimated fetal weight are below the 
lO'h centile (Chauhan et al., 2006). 
With the recent advances in ultrasound technology, it is possible to measure the 
fetal/placental volume with three-dimensional ultrasound (Hafher et al., 2001). 
Comparing the fetal liver volume and renal volume assessed by quantitative 
three-dimensional ultrasound, Chang et al. showed a 97.6% sensitivity and 93.6% 
specificity of fetal liver volume and 96.4% sensitivity and 95.9% specificity of fetal 
renal volume in predicting lUGR using threshold at lO^ '^  percentile (Chang et al.’ 
2006; Chang et a/.，2008). 
2.2.4.2 Biophysical tests 
Biophysical tests, such as Doppler ultrasound, amniotic fluid volume, 
cardiotocography and biophysical scoring, are designed to monitor fetal well-being. 
Among these, Doppler ultrasound is most frequently considered in the diagnosis of 
lUGR. Doppler velocimetry techniques permit the evaluation of fetoplacental 
vascular function, and are thus useful in identifying lUGR fetuses secondary to 
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placental insufficiency (Urban et al., 2007). In lUGR, increased vascular impedance 
in the uterine arteries due to inadequate trophoblast invasion and redistribution of 
fetal blood flow resulting from changes in placental perfusion and substrate 
availability to the fetus can be assessed by Doppler ultrasound (Botsis et al, 2006). 
2.2.4.3 Biochemical tests 
Historically, maternal serum biochemical markers like hPL and estriol were 
developed to monitor placental function and fetal growth (Hensleigh et al, 1977; 
Lilford et al.’ 1983; Gardner et al., 1997). However, the clinical use of biochemistry 
to predict lUGR has been questioned for its poor diagnostic value and was 
abandoned in favor of ultrasound evaluation. Despite this, continual research is 
on-going in hopes of establishing biochemical analytes, including growth hormones 
(GHs), IGFs and leptin, as markers for lUGR (Tjoa et ai, 2004). Recently, low 
levels of maternal serum pregnancy-associated plasma protein-A (PAPP-A) have 
been found to be associated with an increased risk for subsequent delivery of a SGA 
infant in the absence of an abnormal karyotype (Spencer et al., 2008). The same 
group also showed significant decrease of a disintegrin and metallopeptidase domain 
12 (ADAM 12) and PAPP-A in lUGR pregnancies at 11 to 14 weeks (Cowans and 
Spencer, 2007)，bringing insights into first trimester prediction of lUGR using serum 
markers. In another prospective study, instead of analyzing single hormone levels, 
Sorensen et al. showed that the rate of change in serial hPL measurements correlated 
well to intrauterine fetal growth velocity as estimated by third trimester ultrasound 
(Sorensen et aL, 2000). 
2.2.4.4 Others 
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Recently, since the existence of fetal DNA in maternal plasma has opened up 
possibilities for noninvasive prenatal diagnosis (Lo et al., 1997)，scientists also 
explored the quantitative relationship between circulating fetal DNA and fetal 
growth (Caramelli et al, 2003; Sekizawa et al., 2003; Crowley et al., 2007). 
However, these studies are limited by contradictory results and dependence on the 
quantification of the Y-chromosome, which is applicable to male fetuses only. 
2.3 Limitations of current modalities in fetal growth assessment 
In spite of the various modalities developed for the assessment of fetal growth or 
diagnosis of lUGR, none of them is superior. Firstly, ultrasound measurements of 
fetal biometric parameters, though widely used in the clinical assessment of fetal 
growth, fail to differentiate healthy but constitutionally small fetuses from those who 
are growth restricted with the most commonly used below centile cutoff 
(Dudley, 2005). Secondly, biophysical test like Doppler studies have shown to be 
clinically useful in identifying pregnancies at risk of lUGR in high-risk population 
only (Harrington et al., 2004), but poorly applicable to low-risk and mixed 
populations with disappointing sensitivity of just 28% for lUGR requiring delivery 
by 32 weeks (Martin et al, 2001) and 21% for birth weight below the lO^ h centile 
(Albaiges et al.’ 2000). A systematic review by Cnossen et al pointed out that 
abnormal uterine artery waveforms are a better predictor of preeclampsia (PET) than 
of lUGR (Cnossen et al., 2008). Thirdly, maternal serum biochemical markers 
investigated to date for the evaluation of fetal growth had suboptimal diagnostic 
sensitivity and predictive power (Markestad et al.’ 1997; Papadopoulou et al., 2000; 
Barkehall-Thomas et al, 2006). The combination of screening tests, e.g. first 
trimester maternal serum PAPP-A with abnormal uterine artery Doppler (Pilalis et 
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al.’ 2007) or ultrasound crown-rump length (Leung et al., 2008), achieves better 
prediction value, but the sensitivity is still inadequate for efficient clinical screening. 
Finally, recently explored fetal DNA quantification for fetal growth assessment is 
limited to male fetuses only. 
2.4 Aims of this thesis 
Given the many limitations of current methods for fetal growth assessment, and the 
fundamental importance of early recognition of lUGR in attempting to reduce 
adverse perinatal outcomes linked to this problem, it is imperative to develop a 
refined and objective approach for fetal growth monitoring. Cell-free fetal nucleic 
acids in maternal plasma offers a new avenue for noninvasive prenatal diagnosis (Lo 
and Chiu, 2007) and placenta-derived fetal RNA holds promises in the prenatal 
assessment of pregnancy-related conditions (Ng et al” 2003a; Ng et al., 2004; 
Masuzaki et al.’ 2005; Lo et al., 2007b; Sekizawa et al., 2008). Previous reports have 
indicated that the profile of circulating placenta-derived mRNA is reflective of 
placental tissue gene expression (Ng et al, 2004; Tsui et al, 2004). I hypothesized 
that by studying maternal plasma fetal RNA species of placental origin which are 
functionally related to fetal/placental growth, fetal growth could be monitored 
indirectly by detecting the growth-related transcripts in maternal plasma. 
In this thesis, I aim to address for the first time the relationship between circulating 
placental mRNA and fetal growth, as well as to explore the potential utility of 
maternal plasma fetal RNA species in the identification of lUGR. In Chapter 4，I 
described the selection strategy for potential fetal growth RNA markers from a list of 
placenta-derived transcripts generated by microarray analysis of placental tissue. The 
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quantification methods and detection of these markers along gestation were also 
illustrated. In Chapter 5, the relationship between the targeted transcripts and various 
fetal growth indicators were studied. Then in Chapter 6，I investigated the clinical 
application of these targeted transcripts as markers for the prenatal assessment of 
lUGR. 
Finally in Chapter 7, a general conclusion of the studies and the future perspectives 
of circulating fetal RNA as fetal growth markers are discussed. 
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CHAPTER 3: Quantitative Analysis of Circulating RNA 
3.1 Sample collection and processing 
3.1.1 Preparation of plasma 
Peripheral blood samples were collected into ethylenediaminetetraacetic acid 
(EDTA)-containing tubes and centrifuged at 1,600 g for 10 min at 4 °C (Centrifuge 
581 OR, Eppendorf, Hamburg, Germany). The plasma portion was carefully 
transferred to plain polypropylene tubes to be recentrifiiged at 16,000 g for 10 min at 
4 °C (Centrifuge 5415R, Eppendorf) for the removal of any residual blood cells 
(Chiu et al., 2001). The supematants were transferred to fresh polypropylene tubes 
without disturbing the cell pellet. To maintain the RNA integrity, 4.8 mL TRIzol LS 
reagent (Invitrogen, Carlsbad, CA) was mixed thoroughly with every 1.6 mL plasma 
harvested after the double-centrifligation step (Lo et al., 2007b). The resulting 
mixture was kept at -80 °C. 
3.1.2 Preparation of blood cells 
Peripheral blood samples collected into EDTA-containing tubes were centrifuged at 
1,600 g for 10 min at 4 °C. The blood cell fraction was transferred to plain 
polypropylene tubes and recentrifiiged at 2,300 g for 5 min to remove residual 
plasma. After that, 300 |xL of the blood cell portion was added to 900 \iL of TRIzol 
LS reagent and then stored at -80 °C. 
3.1.3 Preparation of placental tissues 
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Placental tissues were collected after elective caesarean delivery or normal vaginal 
delivery. They were cut into small pieces, rinsed with diethyl-pyrocarbonate (DEPC) 
(Sigma-Aldrich, St. Louis, MO)-treated water, and then incubated in RNAlater 
(Ambion, Austin, Texas) stabilizing solution at 4 °C overnight. Samples were stored 
at -80 °C with RNA/ater removed. 
3.2 Total RNA extraction 
3.2.1 Plasma and blood cells 
Plasma and blood cell RNA was extracted by a protocol integrating the use of TRIzol 
LS reagent and the RNeasy Mini Kit (Qiagen, Hilden, Germany) (Figure 3.1)，which 
yields higher amount of RNA than by each method alone (Wong et al, 2004). The 
TRIzol LS reagent, a mono-phasic solution of phenol and guanidine isothiocyanate, 
is an improvement to the single-step RNA isolation method developed by 
Chomczynski and Sacchi (Chomczynski and Sacchi, 1987). Its highly-denaturing 
property is capable to disrupt cells and dissolve cell components, inactivate RNases 
and thus, simultaneously preserve the integrity of the RNA. The RNeay Mini Kit is a 
column-based method for RNA isolation, which has combined the selective binding 
properties of a silica-gel-based membrane with the speed of microspin technology. It 
does not require cesium-chloride gradient ultracentrifugation, and therefore, provides 
a fast and simple protocol for the purification of total RNA from blood and tissue 
samples. 
Total RNA was extracted from the TRIzol LS-plasma mixture and 1.28 mL 
chloroform was added to each aliquots of the mixture containing 1.6 mL plasma. For 
the isolation of total RNA from blood cells, 240 |LIL of chloroform was added to the 
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TRIzol LS-buffy coat mixture. The tubes were shook vigorously by hand and the 
mixture was centrifuged at 12,000 g for 15 min at 4 °C. By then, the mixture was 
separated into different phases with RNA in the aqueous phase, DNA in the organic 
phase, and proteins at the interphase. 
Total RNA in the upper aqueous layer was carefully transferred into new 
polypropylene tubes and then extracted using the RNeasy Mini Kit according to the 
manufacturer's protocols. First, to provide appropriate binding conditions, one 
volume of 70% ethanol was added to one volume of the aqueous layer and mixed by 
inverting the tubes. After that, 700 fiL of the mixture was applied into an RNeasy 
Mini spin column (Qiagen) followed by centrifugation at 9,300 g for 15 sec, during 
which total RNA was absorbed to the membrane. This step was repeated for seven 
more times until all mixture was loaded. Any contaminants were then efficiently 
washed away by adding 350 |xL of Buffer RWl followed by centrifugation with the 
same condition twice plus an additional wash using 500 jxL of Buffer RPE. 
High-speed centrifugation at 16,000 g for 2 min was performed for another wash 
with 500 |iL of Buffer RPE. To ensure complete removal of buffer from the 
membrane, the column was centrifuged at 16,000 g for 2 min. Finally, total RNA 
was eluted with 30 |xL of RNase-free water added directly onto the membrane, and 
then incubated for 5 min at room temperature. In order to maximize the RNA 
extraction yield, the eluate was reloaded to the column and incubated for another 5 
min at room temperature followed by centrifugation at 16,000 g for 1 min. 
To eliminate any genomic DNA contamination, DNase I digestion was performed 
using Amplification Grade DNase I (Invitrogen). 3 \iL each of lOx DNase I Reaction 
Buffer and DNase I was added to 30 |xL of eluted plasma RNA on ice. The reaction 
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mixture was incubated at room temperature for 15 min. After that, DNase I was 
inactivated by the addition of 3 i^L of 25 mM EDTA solution and incubation at 65 °C 
for 10 min. The treated RNA samples were stored at -80 prior to quantitative 
reverse transcriptase-polymerase chain reaction (QRT-PCR) analysis. The DNase I 
digestion protocol for blood cell RNA was same as that for placental tissue RNA 
which will be discussed below. 
30 
Quantitative analysis of circulating RNA 
Plasma/serum > • + ethanol D H 
i i 
+ Trizol LS Reagent , 塞 
+ Ch lo ro fo rm 
Bind total RNA 
M ^ 
I V /— Total RNA 
Aqueous phase 扉 
Figure 3.1 Procedure for RNA extraction from plasma and serum. (Modified 
from RNeasy Mini Handbook, Qiagen, 2001) 
31 
Quantitative analysis of circulating RNA 
3.2.2 Placental tissues 
Each placental tissue sample was homogenized in 3 mL of TRIzol reagent 
(Invitrogen) with a tissue homogenizer (Polytron, Norcross, GA). Cell-debris in the 
homogenate was removed by centrifugation at 11,800 g for 15 min at 4 The 
supernatant was transferred into a new tube and incubated with 0.4 mL of chloroform 
for 3 min at room temperature. The mixture was separated into different phases by 
centrifugation at 12,000 g for 15 min at 4 °C. The upper aqueous phase containing 
total RNA was carefully transferred into fresh tubes and then precipitated with 0.75 
mL isopropyl alcohol for 10 min at room temperature. After centrifugation at 12,000 
g for 10 min at 4 °C, the supernatant was discarded and the RNA pellet was washed 
with 1.5 mL of 75% ethanol, mixed by vortexing and then centrifUged at 7,500 g for 
5 min at 4 °C. After removing the supernatant, the RNA pellet was air-dried and 
dissolved in 30 |iL of RNase-free water. 
The extracted RNA was subjected to DNase I treatment (Invitrogen) according to the 
manufacturer's protocol. Before that, total RNA concentration was quantified using 
the NanoDrop® ND-1000 UV-Vis Spectrophotometer (NanoDrop Technologies, 
Wilmington, DE) for each sample. Then, 1 |Lig of total RNA was mixed on ice with 1 
^L of DNase I，1 |LIL of lOX Reaction Buffer, and RNase-free water to 10 )LIL. The 
reaction mixture was incubated at room temperature for 15 min, followed by the 
addition of 1 i^ L of 25 mM EDTA solution and incubation at 65 "C for 10 min. After 
digestion, the RNA was diluted to a concentration of 1 ng/uL and stored at -80 
prior to QRT-PCR analysis. 
3.3 Quantitative measurements of nucleic acids 
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3.3.1 Principles of real-time quantitative PCR 
Real-time QPCR is a sensitive and reliable method for the detection and 
quantification of nucleic acid levels in a single-tube, single enzyme quantitative 
system. It also eliminates post-PCR processing of PCR products. Hence, this helps to 
increase the throughput，reduces the chance of carryover contamination and removes 
post-PCR processing as a potential source of error (Mackay, 2004). In this thesis, all 
mRNA transcripts were analyzed by one-step real-time QRT-PCR (Gibson et al.’ 
1996) and genomic DNA contamination was checked by real-time QPCR (Heid et al” 
1996) for non-intron spanning assay with the TaqMan system, using the recombinant 
Thermus thermophilus {rTth) and Thermus aquaticus {Taq) DNA polymerase, 
respectively. 
The TaqMan assay (Applied Biosystems, Foster City, CA) consists of a TaqMan 
probe which is a single-stranded synthetic oligonucleotide designed to hybridize to 
the target sequence between the forward and reverse primers (Figure 3.2). It is dually 
labelled, with a fluorescent reporter dye at the 5’ end and a quencher dye at the 3’ 
end. When the probe is intact, the proximity of the quencher greatly reduces the 
fluorescence emitted by the reporter dye through energy transfer. If the target 
sequence is present, the probe anneals to it and is cleaved by the 5’ nuclease activity 
of the DNA polymerase during the extension phase. This separates the reporter and 
the quencher, resulting in an increase in reporter fluorescence emission. The amount 
of fluorescence released is directly proportional to the amount of amplicon produced 
in each PCR cycle and hence can be used to quantify PCR product formation. The 
use of TaqMan probe allows great specificity because only the amplification of the 
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intended sequence is measured, while non-specific amplification due to mis-priming 
or primer-dimer artifact does not generate signal. 
The development of minor groove binding (MGB) probes (Kumar et al., 1998) 
greatly enhances the efficiency and sensitivity of real-time PGR reactions (Kutyavin 
et al, 2000; Afonina et al, 2002) by replacing the standard 3'quencher dye 
(6-carboxy-tetramethyl-rhodamine; TAMRA) with a non-fluorescent quencher 
(NFQ). The higher melting temperatures of MGB probes also allow the design of 
shorter probes that are more specific to their target sequences. Due to the improved 
sensitivity and specificity, I have designed MGB probes for newly established 
real-time QRT-PCR assays {GH2 and ADAM!2 systems). 
Real-time QRT-PCR is carried out in instrumentation capable of combining 
amplification, detection and quantification. All assays described in this thesis were 
performed on the ABI Prism 7300 Sequence Detector or the ABI Prism 7900 
Sequence Detector (Applied Biosystems). Both machines have a built-in thermal 
cycler, a neon lamp or laser to induce fluorescence of the dye, and a charge-coupled 
device camera. Reactions were performed in closed, optical tubes of a 96-well 
microplate. During real-time QRT-PCR, a laser/neon light was directed to each 
reaction via optical fibers and the resulting fluorescent emission data were collected 
with the charge-coupled device camera as the PGR products were being generated. 
Sequence Detection System Software vl.2.3 (Applied Biosystems) analyzes the data 
by first calculating the contribution of each component dye. Each reporter signal is 
then divided by the fluorescence of an internal reference dye for normalization for 
non-PCR related fluorescence fluctuations occurring over time or from well-to-well. 
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Quantification of nucleic acids is achieved by detecting the corresponding threshold 
cycle (Cj). The C j value of an unknown sample is the cycle number at which the 
fluorescence emission exceeds a chosen threshold. This will be plotted on the 
standard curve to determine the starting copy numbers. This value is inversely 
proportional to the starting quantity of the target template. 
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Figure 3.2 TaqMan chemistry. The proximity of the reporter dye and quencher 
dye in an intact probe suppresses reporter fluorescence at the 5' end. During the 
annealing step, the primers and probe bind to their target sequences. During 
polymerization, the probe is displaced and cleaved via the 5' nuclease activity of the 
rTth DNA polymerase. As the reporter dye and quencher dye become separated, 
amplified target can be detected by monitoring the release of reporter fluorescence. 
(Adapted from the TaqMan EZ RT-PCR Kit Protocol, Applied Biosystems, 2002) 
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3.3.2 One-step QRT-PCR assays for placental mRNA quantification 
Four placenta-derived mRNA transcripts, namely CSHl’ growth hormone 2 
(placental growth hormone) {GH2), KiSS-1 metastasis-suppressor (KISSl) and 
ADAM 12 were evaluated for their potentiality to be used as fetal growth markers in 
maternal plasma. They were analyzed in plasma and placental tissues using one-step 
QRT-PCR with specific sequences of primers, probes and calibrators listed in Table 
3.1. The assays were designed to be intron-spanning to avoid genomic DNA 
amplification, except for GH2. It was almost impossible to design specific 
intron-spanning primers for GH2 because the gene shared over 90% sequence 
identity with four other genes also belonging to the human growth hormone gene 
cluster (Chen et al., 1989). For the GH2 non-intron-spanning assay, in addition to 
DNase I treatment as described in Chapter 3.2，negative genomic DNA 
contamination was ensured by no amplification using the AmpliTaq Gold enzyme 
and QPCR (Applied Biosystems) (Chapter 3.3.3). 
The one-step QRT-PCR was set up in a reaction volume of 25 |LIL with components 
provided in the TaqMan EZ RT-PCR Kit (Applied Biosystems) according to the 
manufacturer's instructions. Each reaction was run with 20 ng of buffy coat RNA or 
1 ng of placental tissue RNA or 3 or 5 ^L of extracted plasma RNA. In brief, the 
reaction used the rTth DNA polymerase which functioned both as a reverse 
transcriptase and a DNA polymerase (Myers and Gelfand, 1991). RNA was first 
reverse transcribed to cDNA by sequence-specific primer. PCR amplification of the 
cDNA would then take place. During PCR, the 5' to 3' nucleolytic activity of the 
rTth DNA polymerase then cleaved the hybridized TaqMan probe during PCR 
amplification. Separation of the reporter dye and quencher dye on the same probe 
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resulted in fluorescence signal emission, which was detected and analyzed by the 
sequence detector. 
Table 3.2 illustrates the preparation of the QRT-PCR mixture and the QRT-PCR 
thermal profile using CSHl system as an example. The reaction was initiated at 50 
°C for 2 min for uracil N-glycosylase (UNG) to act, followed by reverse transcription 
at 60 °C for 30 min. After a 5-min denaturation at 95 °C, 45 cycles of PGR were 
carried out with denaturation at 94 °C for 20 s and 1 min of annealing/extension at 56 
°C. The QRT-PCR mix preparation and thermal cycling procedures were the same 
for the other placental genes, with the exception that the primer and probe 
concentrations, plasma RNA input volume and annealing/extension temperature were 
adjusted through optimization to give maximum fluorescence signal in each 
individual system (Table 3.3). 
For absolute quantification of mRNA in terms of copy numbers, a calibration curve 
specifying the studied amplicon was run alongside with the tested samples. The 
calibration curves were prepared by serial dilutions of high performance liquid 
chromatography (HPLC)-purified single-stranded synthetic DNA oligonucleotides 
(Proligo, Helios) with concentrations ranging from 2.5 x 10^  copies to 2.5 copies. 
Such single-stranded oligonucleotides have been demonstrated to reliably mimic the 
products of the reverse transcription step and produce calibration curves that are 
identical to those obtained using TV-transcribed RNA (Bustin, 2000). Each sample 
was analyzed in duplicate with multiple negative water blanks in every analysis. The 
CSHl and GH2 mRNA assays were carried out on an ABI Prism 7300 Sequence 
Detector whereas KISSl and ADAM 12 mRNA were analyzed on an ABI Prism 7900 
Sequence Detector. 
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The absolute mRNA concentration in each sample was calculated using one of the 
following formulas: 
C plasma = Q X ( V RNA / V ext ) 
^ buffy coat/placental tissue = Q / C input RNA 
where C piasma is the mRNA concentration in plasma (copies/mL of plasma); Q is the 
mRNA quantity determined by sequence detector (copies/|iL of RNA sample); V RNA 
is the total volume of RNA solution after the RNA extraction and DNase I treatment 
(typically 39 }xL); V ext is the volume of plasma used for extraction (typically 1.6 
mL); C buffy coat/placental tissue is the mRNA concentration in buffy coat or placental tissue 
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Table 3.2 One-step QRT-PCR assay for quantification of CSHL mRNA. 
(A) One-step QRT-PCR reaction mixture (EZ xTth RNA PGR Reagent Kit; Applied 
Biosystems) 
Components Volume per r e a c t i o n F i n a l concentration 
( M D 
5X TaqMan EZ Buffer 5 IX 
Mn(0Ac)2 (25 mM) 3 3 mM 
dATP(lOmM) 0.75 300 _ 
dCTP(lOmM) 0.75 300 _ 
dGTP(lOmM) 0.75 300 i^M 
dUTP (20 mM) 0.75 600 i^M 
Forward Primer (10 _ 0.75 300 nM 
Reverse Primer (10 jiM) 0.75 300 nM 
TaqMan Probe (5 ]iMf 0.5 100 nM 
AmpErase U N G (1 l]/[iLf 0.25 0.01 U/|LIL 
RM DNA Polymerase (2.5 U/jaL) 1 0.1 U/fiL 
RNase-free water 7.75 -
RNA sample 3 -
Total ^ -
"Dual-labeled fluorescent probe containing a reporter at the 5' end (FAM, 6-carboxyfluorescein) and a 
quencher at the 3' end (TAMRA, 6-carboxytetramethylrhodamine). 
b UNG, uracil-N-glycosylase 
(B) Thermal profile of one-step QRT-PCR reaction 
Step Temperature Time 
UNG treatment 5 0 � C 2 min 
Reverse Transcription 6 0 � C 30 min 
UNG deactivation 9 5 � C 5 min 
Denaturation 94 °C 20 s 
45 Cycles � Annealing / Extension 56 °C 1 min 
41 
Quantitative analysis of circulating RNA 
Table 3.3 Optimized parameters for detection of placenta-expressed transcripts 
using one-step QRT-PCR. 
Plasma R N A P r i m e r and probe “ ~ ~ “ 
Gene input vol腿e concentration (nM) Anneal,ng^mperature 
(^iL) F R P � 
CSHL 3 3 0 0 3 0 0 100 56 °C 
KISSL 3 3 0 0 3 0 0 150 5 7 °C 
GH2 3 3 0 0 3 0 0 2 0 0 5 4 °C 
ADAM12 5 2 0 0 2 0 0 2 0 0 56 °C 
"F, forward primer; R, reverse primer; P, dual-labeled fluorescent probe 
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3.3.3 QPCR assays for checking genomic DNA contamination 
It is important to ensure negative genomic DNA contamination in RNA studies 
because the primers and probes were also complementary to the DNA sequence and 
may lead to false positive amplification. Aside from DNase I treatment after each 
round of RNA extraction, the QRT-PCR assays were designed with a pair of 
intron-spanning primers to control for DNA contamination. For the 
non-intron-spanning assay {GH2 system), absence of genomic DNA was reassured 
by QPCR using the AmpliTaq Gold enzyme. 
With the TaqMan PGR Core Reagent Kit (Applied Biosystems), a reaction volume of 
25 |iL was prepared as described in Table 3.4A. The principle behind the 
quantification is similar to that of QRT-PCR, but QPCR used the AmpliTaq Gold 
DNA polymerase and did not involve the reverse transcription step (Table 3.4B). 
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Table 3.4 QPCR assay for genomic DNA contamination check for GH2 system. 
(A) QPCR reaction mixture (TaqMan PCR Core Reagent Kit, Applied Biosystems) 
Components Volume (^)react ion Final concentration 
lOX TaqMan Buffer A 2.5 IX 
MgClz (25 mM) 4 4 mM 
dATP(lOmM) 0.5 200 ^M 
dCTP(lOmM) 0.5 200 [M 
dGTP (10 mM) 0.5 200 |xM 
dUTP (20 mM) 0.5 400 |iM 
Forward Primer (10 |LIM) 0.75 300 nM 
Reverse Primer (10 |iM) 0.75 300 nM 
Probe (10 ^iMf 1 200 nM 
AmpliTaq Gold® (5 U/|iL) 0.125 0.025 U/ ^L 
AmpErase UNG (1 U/|xL)^ 0.25 0.01 U/ ^L 
Deionized water 10.625 -
Sample 3 
Total 25 -
"Dual-labeled fluorescent probe containing a reporter at the 5' end (FAM, 6-carboxyfluorescein) and a 
quencher at the 3' end {MGBNFQ, Minor-groove binding non-fluorogenic quencher). 
b UNG, uracil-N-glycosylase 
(B) Thermal profile of QPCR reaction 
Step Temperature Time 
UNG treatment 5 0 � C 2 min 
UNG deactivation / AmpliTaq Gold activation 95 °C 5 min 
Denaturation 94 °C 20 s 45 Cycles � Annealing / Extension 5 4 � C 1 min 
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3.4 Statistical analysis 
Statistical analyses were mainly performed using the SigmaStat 3.5 software 
(Systat), except in Chapter 6，the logistic regression software LogXact 8 (Cytel) was 
used for the cross-sectional comparison between lUGR and gestational age matched 
control pregnancies, and longitudinal comparison of repeated measurements between 
lUGR and normal pregnant women was analyzed by multilevel statistical software 
MLwiN 2.0 (CMM). 
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CHAPTER 4: Selection of Potential Fetal Growth mRNA Markers 
for Maternal Plasma Detection 
4.1 Introduction 
Accurate and effective fetal growth monitoring is essential in assuring fetal 
well-being. Growth restriction refers to the inability to fully attain the inherent 
growth potential and is associated with adverse short-term and long-term 
consequences (Lemer, 2004). Various methods have been developed to improve the 
identification of compromised fetuses, including biochemical markers, ultrasound 
biometry and Doppler ultrasound. They are, however, limited by poor detection 
sensitivity or sub-optimal diagnostic value (Markestad et al., 1997; Dudley, 2005; 
Cnossen et al., 2008). Hence, tremendous research work has been devoted to the 
refinement of current modalities for fetal growth assessment, aiming to develop an 
objective means which can identify inadequate in utero growth accurately. 
The discovery of the presence of placenta-derived fetal RNA in maternal plasma has 
generated exciting opportunities for noninvasive prenatal diagnosis (Ng et al, 
2003b). Although circulating fetal DNA markers have been developed and shown to 
be useful in the prenatal assessment of fetal abnormalities or pregnancy disorders, 
they are dependent on paternally-inherited polymorphisms (Lo et al.’ 1998b; Chow et 
al., 2007) or the gender difference between the mother and the fetus (Lo et al, 
1999a; Zhong et al, 2000b). Therefore, circulating fetal RNA species, which can be 
applied to all pregnancies irrespective of both fetal gender and polymorphism status, 
offer a valuable source of fetal genetic material for noninvasive prenatal monitoring. 
For example, aberrant concentrations of placental RNA in maternal plasma were 
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associated with preterm labour (Zhong et al., 2005b), gestational trophoblastic 
disease (Masuzaki et al, 2005), preeclampsia (Ng et al.’ 2004; Zhong et al., 2006; 
Sekizawa et al.’ 2008) and fetal aneuploidies (Ng et al., 2004; Lo et al, 2007b). 
Previously, Tsui et al. have evaluated the expression profile of placental tissues by 
microarray analysis (Tsui et al.’ 2004). In that study, they have systematically 
identified a panel of placenta-derived transcripts that were predominantly expressed 
in the placenta compared to maternal blood cells for both early and late pregnancies 
(Tsui et al., 2004). Genes with placental expression levels beyond a particular 
threshold were shown to be generally detectable in maternal plasma. Notably, the 
relative concentrations of maternal plasma placental mRNA transcripts indeed 
reflected the gene expression pattern in the placenta (Tsui et al, 2004)，suggesting 
their potential clinical usefulness in marker development by disease-specific gene 
expression patterns. 
Base on the study of Tsui et al., I hypothesized that by targeting fetal/placental 
growth-related, placenta-derived mRNA transcripts; one could noninvasively and 
indirectly monitor fetal growth with the transcript levels in maternal plasma. In this 
Chapter, I explored if placenta-derived transcripts could serve as maternal plasma 
RNA markers for fetal growth assessment. First, I selected a number of 
placenta-derived transcripts which were identified by previous microarray analysis 
(Tsui et al，2004) as potential fetal growth markers. Second, I validated if they were 
detectable in maternal plasma and pregnancy-specific. Finally, their gestational 
trends throughout pregnancy were assessed. By doing these experiments, I chose 
transcripts that were most likely to be growth-related for subsequent analyses. 
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4.2 Materials and methods 
4.2.1 Sample collection and processing 
Peripheral blood samples were collected from 10 pregnant women just before and at 
24 hours after elective caesarean delivery (gestational age, 37-39 weeks), 10 
first-trimester (gestational age, 11-13 weeks), 10 second-trimester (gestational age, 
17-22 weeks) and 10 third-trimester (gestational age, 37-39 weeks) uncomplicated 
singleton pregnancies. Serial blood samples were obtained on monthly basis from 15 
pregnant women whose fetuses were not suspected of suffering from lUGR 
(gestational age, 16-40 weeks). Term placental tissue (gestational age, 37-39 weeks) 
was obtained after caesarean delivery from each of 10 pregnant women. All pregnant 
women were recruited with informed consent from the Prince of Wales Hospital, 
Hong Kong. Ethical approval was granted by the Joint Chinese University of Hong 
Kong一New Territories East Cluster Clinical Research Ethics Committee. In 
addition, peripheral blood samples were collected from 10 healthy non-pregnant 
women voluntarily with informed consent. All the samples were processed as 
described in Chapter 3.1. 
4.2.2 Experimental design 
Selection of possible fetal growth RNA markers in maternal plasma 
From the 50 most highly expressed placental transcripts identified by previous 
microarray analysis (Tsui et al., 2004), I chose genes that had been reported to be 
associated with growth physiology as potential fetal growth RNA markers in 
maternal plasma. 
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Development o f quantitative assays for placental m R N A 
Real-time QRT-PCR systems were then developed for the quantification of those 
selected mRNA transcripts. Specific primers and TaqMan MGB probes were 
designed by the software Primer Express 2.0 (Applied Biosystems). I also confirmed 
the placental specificity of these transcripts by comparing their concentrations in 10 
term placental tissue samples and 10 buffy coat samples. 20-fold more buffy coat 
than placental RNA samples was loaded for each reaction in order to eliminate the 
possibility that these transcripts were undetectable in maternal blood cells due to low 
input amount. A placenta-specific transcript should be very much highly-expressed 
in the placenta when compared to maternal blood cells which were likely to 
contribute to the background maternal-derived RNA in maternal plasma (Lui et al.’ 
2002; Tsui et al, 2004; Chim et al, 2005). 
Detectabilitv and post-partum clearance of placental mRNA in maternal plasma 
I first confirmed if the selected mRNA transcripts could be detected in maternal 
plasma and were pregnancy-specific. Detectability was evaluated in the plasma of 10 
non-pregnant women, 10 first-trimester (gestational age, 11-13 weeks), 10 
second-trimester (gestational age, 17-22 weeks) and 10 third-trimester (gestational 
age, 37-39 weeks) uncomplicated singleton pregnancies. Pregnancy-specificity was 
checked by measuring the mRNA concentrations in paired pre- and 24-hour 
post-delivery plasma from 10 healthy pregnant women (gestational age, 37-39 
weeks). 
Cross-gestational analysis of placental mRNA in maternal plasma 
Gestational trends of the selected mRNA transcripts were assessed by cohort group 
comparison and individual serial monitoring. For the former, mRNA concentrations 
50 
Selection of potential fetal growth mRNA markers for maternal plasma detection 
in plasma were compared from 30 pregnant women at various stages of gestation, in 
which 10 women were at the first trimester (gestational age, 11-13 weeks), 10 
women were at the second trimester (gestational age, 17-22 weeks) and 10 women 
were at the third trimester (gestational age, 37—39 weeks). On the other hand, serial 
blood samples were collected on a monthly basis for 3-5 months (gestational age, 
16-40 weeks) from 15 pregnant women whose fetuses were not suspected of 
suffering from lUGR. The maternal plasma concentrations of the selected mRNA 
transcripts for each individual were monitored to evaluate the gestational trend. 
Along with positive fetal/placental growth, a positive trend throughout pregnancy 
should be seen if the transcripts were growth-related. 
4.2.3 RNA extraction and quantification 
Total RNA was extracted from plasma, blood cells and placental tissue with the 
protocols illustrated in Chapter 3.2. All target transcripts were quantified using 
one-step QRT-PCR as described in Chapter 3.3.2. Negative genomic DNA 
contamination was confirmed for the GH2 non-intron spanning assay as suggested in 
Chapter 3.3.3• 
4.2.4 Statistical analysis 
Statistical analyses were performed using the SigmaStat 3.5 software (Systat). 
Mann-Whitney test was performed for the comparison of mRNA concentrations 
between placental tissue and maternal blood cells. Kruskal-Wallis test was used for 
the comparison of maternal plasma mRNA concentrations between different stages of 
pregnancy and non-pregnant subjects. Wilcoxon test was used for the comparison of 
maternal plasma mRNA concentrations before and at 24-hour post-delivery. The 
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slope describing the rate of change of plasma marker levels in each individual was 
generated by linear regression. 
4.3 Results 
4.3.1 Identification of potential fetal growth mRNA markers in maternal 
plasma 
By comparing the gene-expression profiles of the placenta and maternal blood cells, 
a microarray-based strategy was previously established for identifying placental 
mRNA that would be detectable in maternal plasma (Tsui et al, 2004). Mining from 
this data set, I aimed to target transcripts that were functionally related to growth or 
lUGR pathophysiology as potential markers for fetal growth assessment. 
Interestingly, genes belonging to the somatotrophic axes, namely CSHlond GH2 
(Gluckman and Pinal, 2002), and genes involved in fetal or placental development, 
namely KISS I and ADAM12 (Shi et al., 2000; Bilban et al., 2004)，were found 
among the 50 most highly expressed placental transcripts (Tsui et al.’ 2004) in both 
the first (Table 4.1) and third (Table 4.2) trimester lists. Their relative expression 
differences between placental tissues and maternal blood cells (denoted by fold 
differences) and absolute expression (denoted by intensity units of microarray 
expression signals) are shown in Table 4.3. CSHl, GH2’ KISSl and ADAM 12 were 
selected as potential fetal growth RNA markers and subsequently analyzed in various 
experiments in this thesis. 
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Table 4.1 Microarray detection of the 50 most highly expressed genes in CVS 
tissue. (Modified from Tsui et al., 2004) 
G e n B a n k S i g n a l s 
T r a n s c r i p t P r o b e s e t ID a c c e s s i o n n o ( m e d i a n ) 
c h o r i o n i c g o n a d o t r o p i n , B p o l y p e p t i d e 2 0 5 3 8 7 _ s _ a t N M _ 0 0 0 7 3 7 . 1 3 1 8 5 7 . 3 
p l a c * n t a " a c t o g e n (V 4) 208356_x_a t N M _ 0 2 2 6 4 2 . 1 28651.4 
g r o w t h h o r m o n e 1 ( v 5 ) 2 0 8 0 6 8 _ x _ a t N M _ 0 2 2 5 6 2 . 1 2 8 5 0 0 . 7 
g r o w t h h o r m o n e 1 ( v 4 ) 2 0 8 0 6 9 _ x _ a t N M _ 0 2 2 5 6 1 . 1 2 7 6 2 4 . 7 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e 2 ( v 1 ) 2 0 3 8 0 7 一 x _ a t N M 一 0 2 0 9 9 1 . 2 2 7 5 1 3 . 2 
p l a c e n t a l l a c t o g e n ( c l o n e M G C : 1 4 5 1 8 ) 211739_x_a t BC005921 .1 27185.9 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e - l i k e 1 ( v . 2 ) 2 0 8 2 9 4 _ x _ a t N M _ 0 2 2 5 7 8 . 1 2 7 1 0 4 . 4 
p l a c e n t a l l a c t o g e n (v 1) 202493_x_a t NM_001317 .2 26503 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e 2 ( v 3 ) 2 0 8 3 4 2 _ x _ a t N M _ 0 2 2 6 4 5 . 1 2 5 8 2 0 . 6 
p l a c e n t a l l a c t o g e n < v 3 ) 2 0 8 3 5 7 _ x _ a t N M _ 0 2 2 6 4 1 . 1 2 5 7 7 7 . 3 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e 2 ( v 4 ) 2 0 8 3 4 1 _ x _ a t N M _ 0 2 2 6 4 6 . 1 2 5 6 0 3 . 1 
p r e g n a n c y s p e c i f i c B - 1 - g l y c o p r o t e i n 1 2 0 8 2 5 7 _ x _ a t N M _ 0 0 6 9 0 5 . 1 2 5 4 5 3 . 4 
g r o w t h h o r m o n e 1 ( v 2 ) 2 0 6 8 8 5 _ x _ a t N M _ 0 2 2 5 5 9 . 1 2 4 8 3 4 . 8 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e - l i k e 1 ( v 1 ) 2 0 7 2 8 5 _ x _ a t N M _ 0 0 1 3 1 8 . 2 2 4 7 9 6 . 9 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e - l i k e 1 ( v 5 ) 2 0 8 2 9 3 _ x _ a t N M 一 0 2 2 5 8 1 . 1 2 4 7 0 9 . 4 
p r e g n a n c y s p e c i f i c S - 1 - g l y c o p r o t e i n 6 2 0 9 7 3 8 _ x _ a t M 3 1 1 2 5 , 1 2 4 3 7 0 . 6 
p r e g n a n c y s p e c i f i c S - 1 - g l y c o p r o t e i n 3 2 0 3 3 9 9 一 x _ a t N M 一 0 2 1 0 1 6 . 1 2 4 2 6 2 . 4 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e - l i k e 1 ( v 4 ) 2 0 8 2 9 5 _ x _ a t N M _ 0 2 2 5 8 0 . 1 2 4 1 9 0 . 7 
t i s s u e f a c t o r p a t h w a y i n h i b i t o r 2 2 0 9 2 7 8 _ s _ a t L 2 7 6 2 4 . 1 2 4 1 7 9 . 9 
g l y c o p r o t e i n h o r m o n e s . o ： p o l y p e p t i d e 2 0 4 6 3 7 _ a t N M _ 0 0 0 7 3 5 . 2 2 3 7 2 0 . 4 
g r o w t h h o r m o n e 1 ( v 3 ) 2 0 6 8 8 6 _ x _ a t N M _ 0 2 2 5 6 0 . 1 2 3 4 7 5 . 7 
p r e g n a n c y s p e c i f i c B - 1 - g l y c o p r o t e i n 3 2 1 5 8 2 1 _ x _ a t A B 0 1 9 5 7 0 . 1 2 3 0 9 5 . 5 
p r e g n a n c y s p e c i f i c a - 1 - g l y c o p r o t e i n 3 2 1 1 7 4 1 _ x _ a t B C 0 0 5 9 2 4 . 1 2 3 0 2 5 . 1 
| g r o w t h h o r m o n e v a r i a n t m R N A 211151_x_a t AF185611 .1 22792.2 | 
p r o s t a t e d i f f e r e n t i a t i o n f a c t o r 2 2 1 5 7 7 _ x _ a t A F 0 0 3 9 3 4 . 1 2 2 6 8 5 . 4 
g r o w t h h o r m o n e 1 ( v 1 ) 2 0 5 8 4 0 _ x _ a t N M _ 0 0 0 5 1 5 . 2 2 2 4 4 6 . 6 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e - l i k e 1 ( v 3 ) 2 0 5 9 5 8 _ x _ a t N M _ 0 2 2 5 7 9 . 1 2 2 0 9 7 . 6 
p r e g n a n c y s p e c i f i c Q - l - g l y c o p r o t e i n 4 2 0 8 1 9 1 _ x _ a t N M _ 0 0 2 7 8 0 . 1 2 0 7 3 0 . 7 
p r e g n a n c y s p e c i f i c B - 1 - g l y c o p r o t e i n 2 2 0 8 1 3 4 _ x _ a t N M _ 0 3 1 2 4 6 . 1 2 0 2 3 3 . 5 
p r e g n a n c y s p e c i f i c Q - 1 - g l y c o p r o t e i n 9 2 0 9 5 9 4 _ x _ a t M 3 4 4 2 1 . 1 1 9 9 3 9 . 4 
| K I 8 S - 1 m > t a s t a s l s - s u p p r « s » o r 2 0 5 5 6 3 _ a t N M _ 0 0 2 2 5 6 . 1 1 9 7 5 5 . 8 j 
p l a c e n t a l l a c t o g e n ( v 2 ) 2 0 6 4 7 5 _ x _ a t N M _ 0 2 2 6 4 0 . 1 1 9 3 6 7 . 1 
p r e g n a n c y s p e c i f i c B - 1 - g l y c o p r o t e i n 5 2 0 4 8 3 0一 x一 a t N M _ 0 0 2 7 8 1 . 1 1 9 1 8 2 . 6 
[ g r o w t h h o r m o w 2 211S08_s_a t A F 0 0 6 0 6 0 . 1 18019.7 | 
S 1 0 0 c a l c i u m b i n d i n g p r o t e i n P 2 0 4 3 5 1 _ a t N M _ 0 0 5 9 8 0 . 1 1 7 9 7 0 . 2 
p r e g n a n c y s p e c i f i c B - l - g l y c o p r o t e i n 6 2 0 8 1 0 6 _ x _ a t N M _ 0 0 2 7 8 2 . 3 1 7 5 6 6 . 8 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e 2 ( v 2 ) 2 0 7 7 7 0 _ x _ a t N M 一 0 2 2 6 4 4 . 1 1 7 2 4 4 . 2 
C D 6 3 a n t i g e n ( m e l a n o m a 1 a n t i g e n ) 2 0 0 6 6 3一 a t N M _ 0 0 1 7 8 0 . 1 1 7 0 6 1 . 2 
A - l i k e 1 h o m o l o g u e ( D r o s o p h i l a ) 2 0 9 5 6 0 _ s _ a t U 1 5 9 7 9 . 1 1 6 4 1 5 . 0 
f i b r o n e c t i n 1 2 1 0 4 9 5 _ x _ a t A F 1 3 0 0 9 5 . 1 1 6 0 4 6 . 9 
H o m o s a p i e n s c D N A : F L J 2 2 0 6 6 f i s , c l o n e H E P 1 0 6 1 1 2 0 2 4 0 9 _ a t X 0 7 8 6 8 1 6 0 2 4 . 8 
f i b r o n e c t i n 1 2 1 6 4 4 2 _ x _ a t A K 0 2 6 7 3 7 . 1 1 5 8 3 4 . 1 
r i b o s o m a l p r o t e i n L 3 1 2 0 0 9 6 3 _ x _ a t N M _ 0 0 0 9 9 3 . 1 1 5 2 5 2 . 6 
a dislntagrin and metalloproteinase domain 12 (v 2) 2 0 4 9 4 3 _ a t N M _ 0 2 1 6 4 1 . 1 1 5 0 0 7 . 3 
c o l l a g e n , t y p e 1 ( c l o n e H E M B A 1 0 0 1 0 7 1 ) 2 1 5 0 7 6 _ s _ a t A U 1 4 4 1 6 7 1 4 9 9 9 . 1 
p r e g n a n c y s p e c i f i c S - 1 - g l y c o p r o t e i n 9 2 0 7 7 3 3 _ x _ a t N M _ 0 0 2 7 8 4 . 1 1 4 8 1 9 . 7 
s e c r e t e d p h o s p h o p r o t e i n 1 2 0 9 8 7 5 _ s _ a t M 8 3 2 4 8 . 1 1 4 6 6 5 . 3 
E p s t e i n - B a r r v i r u s i n d u c e d g e n e 3 2 1 9 4 2 4 _ a t N M _ 0 0 5 7 5 5 . 1 1 4 6 1 7 . 0 
c o l l a g e n , t y p e l l l i * 1 2 0 1 8 5 2 _ x _ a t A 1 8 1 3 7 5 8 1 4 4 9 4 . 7 
f i b r o n e c t i n 1 2 1 1 7 1 9 _ x _ a t B C 0 0 5 8 5 8 . 1 1 4 1 5 7 . 1 
Transcripts were ranked according to the medians of the five CVS microarray expression signals. 
\ transcript variant; yellow, chorionic somatomammotropin hormone 1 (placental lactogen) (CSHl); 
purple, growth hormone 2 (GH2); orange, a disintegrin and metallopeptidase domain 12 (ADAM12); 
light blue, KiSS-1 metastasis-suppressor (KISSl) 
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Table 4.2 Microarray detection of the 50 most highly expressed genes in term 
placental tissue. (Modified from Tsui et al.，2004) 
GenBank S igna ls 
T r a n s c r i p t Probe set ID access ion no (med ian ) 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e 2 ( v 1 ) 2 0 3 8 0 7 _ x _ a t N M _ 0 2 0 9 9 1 . 2 3 5 7 6 8 . 0 
p lacen ta l lac togan ( c l o n * MGC:1451) 211739_x_at BC005921.1 35732.4 
p l a c e n t a l l a c t o g e n ( v 4 ) 2 0 8 3 5 6 _ x _ a t N M _ 0 2 2 6 4 2 . 1 3 5 0 9 9 . 3 
p l a c e n t a l l a c t o g e n ( v 1 ) 2 0 2 4 9 3 _ x _ a t N M _ 0 0 1 3 1 7 . 2 3 3 9 7 2 . 4 
g r o w t h h o r m o n e 1 ( v 5 ) 2 0 8 0 6 8 _ x _ a t N M _ 0 2 2 5 6 2 . 1 3 3 2 6 5 . 8 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e - l i k e 1 ( v 2 ) 2 0 8 2 9 4 _ x _ a t N M _ 0 2 2 5 7 8 . 1 3 2 9 4 7 . 1 
p l a c e n t a l l a c t o g e n ( v 3 ) 2 0 8 3 5 7 _ x _ a t N M _ 0 2 2 6 4 1 . 1 3 2 8 2 6 . 0 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e 2 ( v 4 ) 2 0 8 3 4 1 _ x _ a t N M _ 0 2 2 6 4 6 . 1 3 2 2 3 1 . 7 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e 2 ( v 3 ) 2 0 8 3 4 2 _ x _ a t N V I _ 0 2 2 6 4 5 . 1 3 1 6 2 3 . 2 
g r o w t h h o r m o n e 1 ( v 4 ) 2 0 8 0 6 9 _ x _ a t N M _ 0 2 2 5 6 1 . 1 3 0 5 2 4 . 9 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e - l i k e 1 ( v 4 ) 2 0 8 2 9 5 _ x _ a t N M _ 0 2 2 5 8 0 . 1 3 0 3 4 9 . 2 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e - l i k e 1 ( v 5 ) 2 0 8 2 9 3 _ x _ a t N M _ 0 2 2 5 8 1 . 1 3 0 0 7 6 . 9 
g r o w t h h o r m o n e 1 ( v 2 ) 2 0 6 8 8 5 _ x _ a t N M _ 0 2 2 5 5 9 . 1 2 9 8 8 8 . 7 
p r e g n a n c y s p e c i f i c B - 1 - g l y c o p r o t e i n 9 2 0 9 5 9 4 _ x _ a t M 3 4 4 2 1 . 1 2 9 4 6 2 . 1 
g r o w t h h o r m o n e 1 ( v 1 ) 2 0 5 8 4 0 _ x _ a t N M _ 0 0 0 5 1 5 . 2 2 8 8 5 6 . 8 
p r e g n a n c y s p e c i f i c B - 1 - g l y c o p r o t e i n 6 2 0 9 7 3 8 _ x _ a t M 3 1 1 2 5 . 1 2 8 7 3 6 . 3 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e - l i k e 1 , ( v 1 ) 2 0 7 2 8 5 一 x _ a t N M _ 0 0 1 3 1 8 . 2 2 8 5 3 2 . 6 
g r o w t h h o r m o n e 1 ( v 3 ) 2 0 6 8 8 6 _ x _ a t N M _ 0 2 2 5 6 0 . 1 2 7 5 7 6 . 2 
p r e g n a n c y s p e c i f i c a - 1 - g l y c o p r o t e i n 1 2 0 8 2 5 7 _ x _ a t N M 一 0 0 6 9 0 5 . 1 2 6 5 2 1 . 2 
p r e g n a n c y s p e c i f i c B - 1 - g l y c o p r o t e i n 3 2 1 1 7 4 1 _ x _ a t B C 0 0 5 9 2 4 . 1 2 6 3 0 6 . 1 
jgrowth hormon* variant (OHV) mRNA 211151人a t AF185611.1 26127.2 ] 
p r e g n a n c y s p e c i f i c B - 1 - g l y c o p r o t e i n 3 2 0 3 3 9 9 _ x _ a t N M 一 0 2 1 0 1 6 . 1 2 5 9 8 7 . 8 
p lacen ta l lac togen (v 2) 206475_x_at NM_022640.1 25873.3 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e - l i k e 1 ( v 3 ) 2 0 5 9 5 8 _ x _ a t N M 一 0 2 2 5 7 9 . 1 2 5 5 9 7 . 7 
a dislntegrln and matalloproteinas* domain 1 2 ( v 2 ) 2 0 4 9 4 3 _ a t N M一021641.1 2 5 5 9 2 . 8 
p r e g n a n c y s p e c i f i c B - 1 - g l y c o p r o t e i n 3 2 1 5 8 2 1 一 x _ a t A B 0 1 9 5 7 0 . 1 2 4 9 4 4 . 4 
t i s s u e f a c t o r p a t h w a y i n h i b i t o r 2 2 0 9 2 7 8 _ s _ a t L 2 7 6 2 4 . 1 2 4 8 9 6 . 4 
g l y c o p r o t e i n h o r m o n e s , p o l y p e p t i d e 2 0 4 6 3 7 _ a t N M 一 0 0 0 7 3 5 . 2 2 4 8 3 1 . 5 
p r e g n a n c y s p e c i f i c R - 1 - g l y c o p r o t e i n 5 2 0 4 8 3 0 _ x _ a t N M 一 0 0 2 7 8 1 . 1 2 3 9 2 8 . 8 
p r e g n a n c y s p e c i f i c ft-l-glycoprotein 2 2 0 8 1 3 4 _ x _ a t N M 一 0 3 1 2 4 6 . 1 2 3 7 8 6 . 0 
p r e g n a n c y s p e c i f i c f l - 1 - g l y c o p r o t e i n 4 2 0 8 1 9 1 _ x _ a t N M _ 0 0 2 7 8 0 . 1 2 3 4 7 5 . 2 
c h o r i o n i c s o m a t o m a m m o t r o p i n h o r m o n e 2 ( v 2 ) 2 0 7 7 7 0 一 x _ a t N M 一 0 2 2 6 4 4 . 1 2 2 2 2 7 . 9 
p r e g n a n c y s p e c i f i c & - 1 - g l y c o p r o t e i n 9 2 0 7 7 3 3 _ x _ a t N M _ 0 0 2 7 8 4 . 1 2 2 0 8 8 . 4 
p r o s t a t e d i f f e r e n t i a t i o n f a c t o r 2 2 1 5 7 7 _ x _ a t A F 0 0 3 9 3 4 . 1 2 0 3 3 5 . 8 
c y t o c h r o m e P 4 5 0 , s u b f a m i l y X I X 2 0 3 4 7 5 _ a t N M _ 0 0 0 1 0 3 . 1 2 0 1 4 7 . 5 
A - l i k e 1 h o m o l o g u e ( D r o s o p h l l a } 2 0 9 5 6 0 一 s _ a t U 1 5 9 7 9 . 1 1 9 2 6 8 . 5 
p r e g n a n c y s p e c i f i c B - 1 - g l y c o p r o t e i n 6 2 0 8 1 0 6 _ x _ a t N M _ 0 0 2 7 8 2 . 3 1 9 2 2 5 . 4 
H o m o s a p i e n s c D N A F L J 3 9 3 9 9 f i s , c l o n e P L A C E 6 0 1 1 0 4 1 2 1 3 3 3 2 _ a t A L 0 3 1 2 9 0 1 8 5 2 4 . 9 
S 1 0 0 c a l c i u m b i n d i n g p r o t e i n P 2 0 4 3 5 1 _ a t N M _ 0 0 5 9 8 0 . 1 1 8 4 8 0 . 2 
H o m o s a p i e n s c D N A : F L J 2 2 0 6 6 f i s . c l o n e H E P 1 0 6 1 1 2 0 2 4 0 9 _ a t X 0 7 8 6 8 1 7 5 1 8 . 8 
C D 5 9 a n t i g e n p 1 8 - 2 0 2 0 0 9 8 3 _ x _ a t N M _ 0 0 0 6 1 1 . 1 1 7 2 9 5 . 0 
c o r t i c o t r o p i n r e l e a s i n g h o r m o n e 2 0 5 6 3 0 _ a t N M _ 0 0 0 7 5 6 . 1 1 7 0 7 6 . 6 
a disintegrin and m*tal loprotelnas* domain 12 (v 1) 2 0 2 9 5 2 _ s _ a t NM_003474.2 1 6 9 9 2 . 6 
g r o w t h h o r m o n e 2 2 1 1 5 0 8 _ s _ a t A F 0 0 6 0 6 0 . 1 1 6 2 5 1 . 8 
p r e g n a n c y s p e c i f i c B - 1 - g l y c o p r o t e i n 7 2 0 5 6 0 2 _ x _ a t N M _ 0 0 2 7 8 3 . 1 1 6 1 7 4 . 5 
[ K i S S - 1 mtta»tasls-«upprt«sor 2 0 5 5 6 3 _ a t N M _ 0 0 2 2 5 6 . 1 1 6 0 3 3 . 3 [ 
d i p e p t i d y l p e p t i d a s e 7 2 0 0 8 7 8 _ a t A F 0 5 2 0 9 4 . 1 1 5 2 2 7 . 5 
h y d r o x y - ^ 5 - s t e r o i d d e h y d r o g e n a s e , 3 ( I - a n d s t e r o i d A - i s o m e r a s e 1 2 0 4 5 1 5 _ a t N M _ 0 0 0 8 6 2 . 1 1 4 3 9 4 . 6 
H o m o s a p i e n s m R N A f u l l l e n g t h i n s e r t c D N A c l o n e E U R O I M A G E 1 6 9 5 5 3 2 2 0 1 9 8 1 _ a t A A 1 4 8 5 3 4 1 4 2 7 7 . 2 
f i b u l i n 1 2 0 1 7 8 7 _ a t N M _ 0 0 1 9 9 6 . 1 1 4 0 2 0 . 6 
transcripts were ranked according to the medians of the five term placental tissue microarray 
expression signals. 
\ transcript variant; yellow, chorionic somatomammotropin hormone 1 {placental lactogen) iCSHl); 
purple, growth hormone 2 (GH2); orange, a disintegrin and metallopeptidase domain 12 {ADAM12); 




























































































































































































































































































































































































































































































Selection of potential fetal growth mRNA markers for maternal plasma detection 
4.3.2 Development of real-time QRT-PCR assays 
Placental mRNA transcripts in maternal plasma were quantified by QRT-PCR (Ng et 
a/.，2003b). Among the four selected transcripts, I have developed real-time 
QRT-PCR assays for the maternal plasma detection of GH2 and ADAM12 mRNA 
which were previously unexplored for noninvasive prenatal monitoring. First of all, 
the quantitative performance of the GH2 and ADAM 12 assays were determined by 
amplifying the corresponding serially diluted calibrators made of synthetic DNA 
oligonucleotides. The calibration curves, specifying the amplicon sequences, for the 
GH2 and ADAM 12 amplification systems displayed a dynamic range from 2.5 x 10^  
to 2.5 copies (Figure 4.1). For the GH2 calibration curve, the gradient was -3.9 and 
correlation coefficient {R') was 0.999. For the ADAM 12 calibration curve, the 
gradient was -3.43 and R^ was 0.999 (Figure 4.1). Using these systems, GH2 and 
ADAM12 were found to be expressed abundantly in 10 term placental tissue samples 
relative to 10 maternal whole blood samples. In placental tissue, the median of GH2 
and ADAM 12 were 57657 copies/ng total RNA and 112721 copies/ng total RNA, 
respectively. In buffy coat, the median of GH2 and AD AM 12 were 1 copy/ng total 
RNA and 3 copies/ng total RNA, respectively, which were significantly lower than 
those in placental tissues (Mann-Whitney test, P < 0.001 for both transcripts). These 
















































































































































































































































































































































































































Selection of potential fetal growth mRNA markers for maternal plasma detection 
Figure 4.1 Amplification plots obtained using one-step QRT-PCR for the (A) 
GH2 and (B) ADAM 12 calibration standards. Each plot corresponds to a particular 
input target quantity (copies/|iL) run in duplicates. The ；c axis denotes the cycle 
number of the one-step QRT-PCR. The 少 axis denotes the ARn, which is the 
fluorescence intensity over the background. Plots of the threshold cycle (Cj) against 
the input target quantity (common log scale) for the (C) GH2 and (D) ADAM12 
calibration standards. 
4.3.3 Validation of maternal plasma detectability and pregnancy-specificity 
To establish circulating placental mRNA in maternal plasma as markers for 
noninvasive prenatal monitoring, I first confirmed if the four selected transcripts 
could be detected in maternal plasma and were pregnancy-specific. Previously, 
CSHl mRNA was found to be detectable in all three trimesters of pregnancy (Ng et 
al.’ 2003b; Okazaki et al., 2006), but undetectable in non-pregnant subjects (Okazaki 
et al., 2006) and post-delivery plasma samples (Ng et al, 2003b). KISSl mRNA was 
detected in first and third trimester maternal plasma with detection rate of 50% and 
100%, respectively, and cleared post-partum (Tsui et al, 2004). 
In this study, I showed that KISSl, GH2 and ADAM 12 mRNA were 100% detected 
in the plasma of 30 women from all three trimesters of pregnancy (10 samples for 
each trimester). However, in the plasma of 10 non-pregnant women, KISSl mRNA 
had detection rate of only 10% and GH2 mRNA was undetectable, both with median 
concentrations of 0 copy/niL (interquartile range (IQR), 0-0). Relatively minute 
amount of ADAMl2 mRNA was detected in 50% of the non-pregnant samples, with 
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median concentration of 1 copy/mL (IQR, 0-7). Figure 4.2 shows the levels of the 
studied transcripts at different trimesters of pregnancy and in non-pregnant women. 
Table 4.4 summarizes the real-time QRT-PCR results in the plasma detection rate of 
these transcripts in the plasma samples. 
Furthermore, pregnancy-specificity was confirmed with 10 pregnancies with paired 
maternal plasma collected before and at 24 hours after delivery. GH2 mRNA was 
100% detectable in the pre-delivery plasma but only 40% detectable in the 24-hour 
post-delivery plasma, with median concentrations of 671 copies/mL (IQR, 333-1158) 
and 0 copy/mL (IQR, 0-67), respectively (Figure 4.3A). ADAM 12 mRNA was 100% 
detectable in the pre-delivery plasma but 80% detectable in the 24-hour post-delivery 
plasma, with median concentrations of 245 copies/mL (IQR, 133-508) and 10 
copies/mL (IQR, 7-20)，respectively (Figure 4.3B). Statistically significant decrease 
in maternal plasma concentrations of both GH2 and AD AM 12 was observed before 
and after delivery (Wilcoxon test, P = 0.002 for both transcripts). Post-partum 
clearance of CSHl and KISSl has been demonstrated by previous studies (Ng et al., 
2003b; Tsui et al, 2004). 
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Table 4.4 Summary o f real-time QRT-PCR results in the detection rate o f the 
studied transcripts in plasma of non-pregnant women and at various stages of 
pregnancy. 
Interquartile Median, Detection rate, Transcript Sample range (copies/mL) 
(copies/mL) 
KISSl Non-pregnant 0 10 
广 trimester 1152 678-1695 100 
2nd trimester 852 505-1444 100 
3rd trimester m o 701-1876 100 
GH2 Non-pregnant 0 0 
广 trimester 437 317-893 100 
2nd trimester 639 392-1292 100 
3rd trimester 1504 725-2927 100 
ADAM12 Non-pregnant 1 0-7 ^ 
r^ trimester 92 34-120 100 
2nd trimester 83 67-190 100 
3rd trimester 241 146-513 100 
° Detection rates are the percentages of the cases with detectable amounts of the respective mRNAs. 
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Figure 4.2 Box plots of (A) KISSl mRNA (B) GH2 mRNA, and (C) ADAM]2 
mRNA in the plasma of non-pregnant women and healthy pregnant women at 
different stages of gestation. The lines inside the boxes denote the medians. The 
boxes mark the intervals between the and 75^ percentiles. The whiskers denote 
the intervals between the and 90^ percentiles. • indicates a data point outside 
the 10^ and 90^ percentiles. 
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Figure 4.3 Concentrations of (A) GH2 mRNA and (B) ADAM]2 mRNA in 
maternal plasma before and at 24 hours after delivery. Each line represents 
corresponding plasma samples obtained from one pregnancy. 
4.3.4 Assessment of the gestational trend in maternal plasma 
As the fetus is undergoing positive growth along gestation, I reasoned that a positive 
gestational trend could be observed in maternal plasma if the selected markers were 
growth-related. I investigated the mRNA gestational trend by cohort group 
comparison and individual serial monitoring. 
Cohort sroup comparison 
mRNA levels were compared from 10 samples of each of the three trimesters of 
pregnancy. An increasing gestational trend was previously demonstrated for maternal 
plasma CSHl mRNA (Ng et al, 2003b). As shown in Figure 4.2, there are positive 
trends for GH2 and ADAM 12 mRNA, but similar levels of KISSl mRNA across 
various stages of gestation (Kruskal-Wallis test, P = 0.442). Third trimester plasma 
GH2 and ADAM 12 mRNA concentrations were significantly higher than those in the 
second and first trimesters (Kruskal-Wallis test followed by pairwise comparison 
using the Student-Neuman-Keuls test, P = 0.016 for GH2 and P = 0.01 for 
ADAM 12). For GH2, the median of third trimester samples was 3.4- and 2.4-fold 
higher than that of first and second trimester samples, respectively. For AD AMI 2, 
2.6- and 2.9-fold increase were recorded for third trimester samples when compared 
to first and second trimester samples, respectively. Table 4.4 summarises the change 
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in concentrations of all studied transcripts throughout different trimesters of 
pregnancy. 
Individual serial monitoring 
To take a closer look at the gestational trend, I also collected serial blood samples on 
a monthly basis for 3-5 months and monitored the plasma concentrations of CSHl, 
KISSl, GH2 and ADAMl2 mRNA from 15 pregnant women whose fetuses were not 
suspected of suffering from lUGR. For each transcript, I calculated the slope (i.e. the 
rate of increase) with linear regression for the mRNA concentration with all serial 
data points from each individual. A positive slope represents increasing mRNA 
levels along gestation, whereas a negative slope describes a decreasing trend. Figure 
4.4 shows the serial measurements of the different mRNA transcripts in the plasma 
for each individual. As summarized in Table 4.5, the proportion of positive slopes for 
each transcript was evaluated, which could be ranked in descending order as: CSHl 
(100%, \5I\S)>ADAM12 (93%, 14/15) > GH2 (87%, \2>l\5)> KISSl (67%, 10/15). 
Both the cross-gestational and serial analyses showed that plasma CSHl, GH2 and 
ADAM 12 mRNA followed strong positive gestational trends, while plasma KISSl 
mRNA had the least positive slopes and did not show significant increase in 
concentration in the three trimesters of pregnancy. Therefore, KISSl mRNA was 
concluded to have less potential to be growth-related and was thus excluded in 
subsequent analyses. 
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Figure 4.4 Intra-individual variation in plasma mRNA concentrations with 
gestational week. (A: CSH1\ B: GH2\ C: ADAMI2; D: KISSl) 
Table 4.5 Slope values of linear regression curves for plasma placental mRNA 
concentrations against gestational weeks. 
^rate of change of copies/mL mRNA 
Case no. per gestational week 
CSHl ADAM12 GH2 KISSl 
1 411.9 16.7 8.8 137.3 
2 4.0 -2.3 53.7 -26.9 
6 861.4 52.6 167.6 231.6 
9 220.0 6.0 -3.9 34.1 
10 1075.8 17.5 247.4 -7.2 
11 368.9 13.5 43.2 -14.5 
13 146.7 25.7 -129.8 -77.1 
14 715.5 34.7 228.6 450.9 
17 1132.1 27.5 213.1 103.7 
18 140.9 7.6 29.7 -21.9 
20 207.7 6.8 236.7 140.6 
21 1923.9 17.3 178.0 98.9 
26 386.2 28.5 203.8 115.4 
27 488.6 3.8 237.6 49.6 
28 1941.0 168.6 489.7 546.8 
Total case no. 15 15 15 15 
No. of positive slope 15 14 13 10 
No. of negative slope 0 1 2 5 
% of positive slope 100.0 ^ ^ 66.7 
®The slope values represent the rate of change of copies/mL mRNA per gestational week. 
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4.4 Discussion 
In this Chapter, I investigated the possibility of using circulating placental mRNA for 
fetal growth assessment. Previously, it has been demonstrated that there was no 
correlation between the concentration of maternal plasma fetal DNA and placental 
size during the first trimester (Wataganara et al, 2005). While the amount of fetal 
DNA released into maternal plasma is determined by placental apoptosis (Tjoa et al, 
2006a), circulating RNA concentration is additionally influenced by the relative 
placental tissue expression of a gene (Ng et al,’ 2003a; Ng et al., 2003b; Tsui et al, 
2004). Therefore, this prompted the current study of fetal growth by targeting RNA 
transcripts that are related to growth or lUGR pathophysiology. The strategy was 
based on the earlier reported microarray analysis of placental tissues and maternal 
blood cells, which demonstrated that genes with placental expression levels beyond a 
particular threshold were generally detectable in maternal plasma. In the first part of 
the study, I mined from this data set and selected placental mRNA transcripts that 
were reported to be functionally involved in somatic growth, namely CSHl’ GH2, 
KISSl and ADAM12. 
Both CSHl and GH2 belong to the human growth hormone gene family, sharing 
structural similarities and biological activities (Chen et al, 1989). Human placental 
lactogen (hPL), the protein product of CSHl, is secreted into both the maternal and 
fetal circulations after the sixth week of pregnancy. Placental growth hormone 
(PGH), the protein product of GH2’ is a growth hormone (GH) variant expressed in 
the placenta. From 15-20 weeks until term, PGH gradually replaces pituitary GH 
which becomes undetectable in maternal circulation (Hennen et al, 1985). Although 
the exact functions of hPL and PGH have not been entirely elucidated, the available 
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evidence suggests roles for them in the control o f fetal growth and maternal 
metabolism (Fleenor et al., 2005; Freemark, 2006). In the mother, hPL and PGH act 
in concert to stimulate IGF production and regulate intermediary metabolism, 
enhancing the availability of glucose and amino acids to the fetus (Handwerger and 
Freemark, 2000). In the fetus, hPL modulates embryonic development, regulate 
intermediary metabolism and stimulate the production of IGFs, insulin, 
adrenocortical hormones and pulmonary surfactant (Handwerger and Freemark, 
2000). 
In addition to controlling cancer cell dissemination (Lee et al., 1996; Navenot et al.’ 
2005), metastasis suppressor gene KISSl has been recently identified to repress 
trophoblast invasion via binding to the G protein-coupled receptor KiSS-lR (Janneau 
et al.’ 2002; Bilban et al., 2004). Gelatinase matrix metalloproteinases (MMPs) are 
secreted by human first trimester trophoblasts to mediate extracellular matrix 
degradation, allowing migration and invasion (Cohen et al.’ 2006). KISSl transcript 
product, kisspeptin, suppresses one or both of the MMP-2 and MMP-9 (Yan et al., 
2001; Bilban et al” 2004; Qiao et al, 2005)，which in turn regulates placental 
development. 
ADAM 12，a pregnancy-associated member of the ADAM multidomain glycoprotein 
family, contributes to fetal growth through its strong proteolytic activity. It binds to 
and cleaves IGFBP-3 and IGFBP-5 (Loechel et al, 2000)，which considerably 
reduces their affinity for the IGFs (Blat et al., 1994) and thus increases IGFs 
bioavailability. IGF proteins are the major growth factors involved in preparation of 
the endometrium for implantation (Merviel et al,’ 2001) and maintaining the decidua 
of the placenta. 
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As these genes are related to placental and fetal development, I hypothesized that the 
plasma level of the corresponding RNA transcripts might reflect fetal growth 
indirectly. In the second part, I developed QRT-PCR assays for GH2 and ADAM 12 
mRNA that were previously unexplored for noninvasive prenatal monitoring. Using 
these assays, I was able to prove the placental specificity of these transcripts which 
was in agreement with the microarray expression profile (Tsui et al, 2004). 
Being studied for the first time, GH2 and ADAM!2 mRNA were readily detectable in 
maternal plasma of all three trimesters of pregnancy, but not to any substantial extent 
in nonpregnant subjects. This further confirmed the validity of the previously 
reported microarray strategy for identifying placental mRNA markers detectable in 
maternal plasma (Tsui et al., 2004). Post-partum clearance from maternal plasma 
confirmed that they were pregnancy-specific. My modifying the probe concentration 
in the KISSl QRT-PCR assay from 200 nM to 150 nM, the detection rate has 
increased from 50% (Tsui et al., 2004) to 100% in first trimester plasma samples. 
Finally, to determine whether the selected transcripts were likely to be 
growth-related, I assessed if a positive gestational trend could be seen in a cohort of 
cases from the three trimesters of pregnancy as well as individual serial assessment. 
By comparing the concentrations of the selected transcripts at different stages of 
pregnancy and evaluating the proportion of positive trends for each marker 
demonstrated by several individuals, I have shown that maternal plasma CSHl, GH2 
^ and ADAM 12 mRNA increased throughout pregnancy, along with positive fetal 
growth, while plasma KISSl mRNA level did not. Previous studies have shown 
gestation-related variations in fetal RNA, namely CSHl, (5-hCG and CRH (Ng et al” 
2003b; Farina et al, 2004)，and CRH concentrations in maternal plasma are normally 
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distributed at each gestational interval (Farina et a l . , 2004). The plasma m R N A 
levels of CSHl correlate with the corresponding protein levels at various gestational 
ages (Ng et al, 2003b). The observed gestational variation of circulating GH2 and 
ADAM 12 also resembles the trends exhibited by the corresponding proteins as 
published in literature. PGH starts to increase from mid-trimester and peaks at term 
(Mirlesse et al., 1993). ADAM 12 displays an overall increasing trend (Laigaard et 
al., 2003), with a temporal decrease from 10 to 14 weeks and then rises up again 
until term (Laigaard et al., 2006). Circulating kisspeptin during pregnancy 
(Horikoshi et al.’ 2003) has recently been speculated to be contributed by an 
additional extra-placental source - the hypothalamus (Roa et al, 2006). Since KISSl 
mRNA is much highly expressed in first trimester than term placenta (Janneau et al, 
2002; Bilban et al., 2004) and I am detecting the placenta-derived KISSl mRNA in 
maternal plasma, it is not surprising that there is little increase in KISSl along 
gestation. 
In conclusion, this part of the thesis has described the selection criteria and strategy 
for targeting potential fetal growth markers from microarray analysis of placental 
gene expression profile (Tsui el al, 2004). I have demonstrated for the first time that 
GH2 and ADAM 12 mRNA were detectable in maternal plasma, which has extended 
the list of candidate circulating placental RNA markers that can be applied for 
noninvasive prenatal diagnosis. Moreover, the gestation trends of selected transcripts 
were assessed, showing their concentrations in relation to positive fetal growth along 
gestation. KISSl mRNA in maternal plasma appeared to be less likely to be 
growth-related and was thus excluded from subsequent analysis. Further 
investigations of the relationship between the potential markers and fetal growth 
would be conducted in Chapter 5. 
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CHAPTER 5: Relationship between Circulating Placental mRNA 
and Fetal Growth 
5.1 Introduction 
In the hope of developing fetal growth markers using fetal RNA in maternal plasma, 
I have targeted a few placental transcripts that have been reported to be functionally 
associated with fetal or placental growth. In Chapter 4，it was shown that these 
pregnancy-specific candidates could be detected in maternal plasma with specific 
one-step QRT-PCR assays. From a preliminary investigation between these selected 
transcripts and fetal growth based on gestational trend analysis, I have finalized 
CSHl, GH2 and ADAM 12 mRNA as potential placental transcripts for fetal growth 
marker development. 
Placenta-derived fetal RNA in maternal plasma could provide valuable information 
regarding the gene expression profile of the fetus. It has been demonstrated that the 
relative concentrations of placental mRNA in plasma mirrored the gene expression 
patterns in the placenta (Tsui et al.’ 2004). Aside from this, the placental transcript 
levels in maternal plasma would be potentially affected by (a) placental size; (b) the 
rate of liberation of mRNA transcripts from the placenta into plasma; and (c) the 
clearance rate of the transcripts from the plasma. 
In current clinical practice, assessment and monitoring of fetal growth is mainly 
based on sonographic fetal and placental biometric features and birth weight 
(Goldenberg and Cliver, 1997; Bakketeig, 1998). No one has ever reported the 
relationship between placental mRNA in maternal plasma and fetal growth 
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indicators, while much evidence is available for the correlation between 
growth-related hormones and fetal growth features. For example, maternal hPL， 
IGF-I and PGH levels correlated well with fetal birth weight (Houghton et al.’ 1984; 
Caufriez et al., 1993; Mclntyre et al, 2000; Sorensen et al, 2000). 
In this Chapter, I am going to investigate the unexplored relationship between fetal 
growth and the levels of circulating placental mRNA. I hypothesized that if the 
selected transcripts were indeed growth-related, potential correlation may exist 
between fetal growth parameters, birth measurements and the concentrations of these 
transcripts. Their relationship with growth would be first explored by studying the 
expression in placental tissues obtained from fetuses with different birth weight 
centiles. I further determined if there were correlations between the maternal plasma 
transcript concentrations with fetal and placental weight and fetal biometric 
ultrasound measurements. These experiments would provide valuable information on 
developing potential fetal growth markers from fetal RNA in maternal plasma. 
5.2 Materials and methods 
5.2.1 Sample collection and processing 
35 placental tissue samples (gestational age, 27-41 weeks) were collected after 
elective caesarean or normal vaginal delivery. Pre-delivery blood samples were 
obtained from 33 singleton pregnancies (gestational age, 28-41 weeks). Peripheral 
blood samples were collected from 20 pregnant women at the time of ultrasound 
assessment (gestational age, 19-41 weeks). The recruited samples cover a full range 
of growth centiles. All pregnant women were recruited with informed consent from 
the Prince of Wales Hospital, Hong Kong. Ethical approval was granted by the Joint 
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Chinese University of Hong Kong~New Territories East Cluster Clinical Research 
Ethics Committee. All the samples were processed as described in Chapter 3.1. 
5.2.2 Ultrasound measurement, placental weight and birth weight 
Ultrasound scans for fetal AC, FL, BPD and HC were performed at each assessment 
visit. Placental weight and birth weight were recorded immediately after birth. 
5.2.3 Experimental design 
Expression of potential growth markers in placental tissues 
I first studied if the placental tissue expression of the selected growth-related 
transcripts would be altered with fetal size. Placental tissues were collected after 
delivery from fetuses with a wide range of customized birth weight centiles. The 
absolute placental expression of CSHl, GH2 and ADAM 12 mRNA were measured 
from 35 placental tissues (gestational age, 27 - 41 weeks) and then compared with 
different birth weight centiles. 
Relationship between circulating placental mRNA and birth measurements 
Relationships between the concentrations of plasma placental mRNA and customized 
birth weight centile, birth and placental weight were explored by statistical 
correlation analyses in 33 pregnancies (gestational age, 2 8 ^ 1 weeks). Birth 
measurements, including birth and placental weight, were recorded immediately after 
delivery. The customized birth weight centiles were calculated with the 
corresponding maternal height, booking weight, parity, fetal sex and gestational age 
(Pang et al.’ 2000). Pre-delivery blood was analyzed because it could best reflect the 
situation at birth. 
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Relationship between circulating placental mRNA and fetal biometric measurements 
In order to investigate the relationship between the concentrations of the selected 
transcripts in maternal plasma and fetal growth parameters, blood samples were 
collected at the time of ultrasound assessment from 20 pregnant women bearing 
fetuses with different birth weight centiles (gestational age, 19-41 weeks). 
Ultrasound measurements of AC, FL, BPD and HC were correlated to the 
concentrations of plasma CSHl, GH2 and ADAM 12 mRNA. 
5.2.4 RNA extraction and quantification 
Total RNA was extracted from plasma and placental tissue with the protocols 
illustrated in Chapter 3.2.1 and 3.2.3, respectively. All target transcripts were 
quantified using one-step QRT-PCR as described in Chapter 3.3.2. Negative genomic 
DNA contamination was confirmed for the GH2 non-intron spanning assay as 
suggested in Chapter 3.3.3. 
5.2.5 Statistical analysis 
Statistical analyses were performed using the SigmaStat 3.5 software (Systat). 
Kruskal-Wallis test was used for the comparison of maternal plasma mRNA 
concentrations between different categories of customized birth weight centiles. 
Spearman correlation analyses were performed to investigate the relationship 
between placental mRNA concentrations in maternal plasma and customized birth 
weight centile, birth and placental weight, and fetal biometric measurements. 
5.3 Results 
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5.3.1 Expression of potential growth markers in placental tissues 
First of all, I investigated if the placental tissue expression of the selected 
growth-related transcripts would vary with fetal size. The absolute placental 
expression of CSHl, GH2 and ADAM12 mRNA were measured from placental 
tissues obtained after delivery and then compared between 17 samples with fetal 
customized birth weight below 10''' centile, 14 samples between lO^*" - 90 '^' centile 
and 4 samples above 90'*^  centile. Figure 5.1 shows that there is no significant 
difference between the placental expressions of CSHl (Kruskal-Wallis test, P = 
0.22), GH2 (Kruskal-Wallis test, P = 0.551) and ADAM12 (Kruskal-Wallis test, P = 
0.393) mRNA at different customized birth weight centiles, implicating that the 
absolute expression levels of these transcripts in placental tissues were not affected 
by different fetal size. 
5.3.2 Relationship between circulating placental mRNA and birth 
measurements 
I next studied if CSHl, GH2 and ADAM 12 mRNA concentrations in maternal plasma 
would be related to fetal size. Pre-delivery blood samples were obtained from 33 
singleton pregnancies, consisting of 19 and 14 fetuses with customized birth weight 
below 10th centile and between - 90出 centile, respectively. The correlation 
analyses between the mRNA concentrations with customized birth weight centile, 
placental and birth weight are summarized in Table 5.1. These results demonstrate 
significant positive correlations between birth weight (Spearman correlation analysis, 
r = 0.356 and P = 0.0423) (Figure 5.2A), customized birth weight centile (Spearman 
correlation analysis, r = 0.355 and P = 0.0429) (Figure 5.2B) and plasma GH2 
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mRNA but not for CSHl and AD AM 12 mRNA. Significant negative correlation was 
observed between plasma ADAM12 mRNA and placental weight (Spearman 
correlation analysis, r = -0.349 and P = 0.0467). 
5.3.3 Relationship between circulating placental mRNA and fetal biometric 
measurements 
We finally investigated the potential correlation between fetal ultrasound parameters 
measurements and the plasma placental mRNA concentrations. Blood samples were 
collected at the time of ultrasound assessment with clear record for the measurements 
of AC, FL, BPD and HC from 20 pregnant women who later gave birth to 13 fetuses 
with customized birth weight below centile, 5 between 10'^  - 90 '^' centile and 2 
above 90出 centile. There were 1 and 8 missing measurements of BPD and HC, 
respectively. As shown in Table 5.2 and Figure 5.2C-F, there were a positive 
correlations between maternal plasma GH2 mRNA and 3 out of 4 biometric 
measurements, including AC (Spearman correlation analysis, r = 0.604 and P = 
0.0048)，FL (Spearman correlation analysis, r = 0.59 and P = 0.0063) and BPD 
(Spearman correlation analysis, r = 0.705 and P < 0.001). There was no significant 
correlation between maternal plasma CSHl (Figure 5.3, A-D) and ADAM 12 (Figure 
5.3, E-H) mRNA and the fetal ultrasound measurements. 
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mRNA concentrations in placental tissues of different categories of customized birth 
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Table 5.1 Summary of the Spearman correlation analyses of placental mRNA in 
pre-delivery plasma and placental weight and birth weight. 
Placental weight Birth weight Customized birth weigl 
(n = 33) (n = 33) centile (n = 33) 
Gene r P r P r P 
CSHl -0.165 0.356 -0.0635 0.723 0.11 0.54 
GH2 0.116 0.519 0.356 0.0423* 0.355 0.0429" 
ADAM! 2 -0.349 0.0467* -0.121 0.498 -0.0495 0.783 
a n, sample size; r, correlation coefficient; P, p-value; and * denotes statistical significance 
Table 5.2 Summary of the Spearman correlation analyses of placental mRNA in 
maternal plasma and fetal biometric measurements. 
AC (n = 20) FL (n = 20) BPD (n = 19) 
Gene r P r P r P 
CSHl 0.292 0.208 0.339 0.14 0.154 0.521 
GH2 0.604 0.0048* 0.59 0.0063* 0.705 <0.001* 
ADAM12 0.304 0.189 0.306 0.184 0.254 0.288 
"n, sample size; r, correlation coefficient; P’ p-value; and * denotes statistical significance 
''AC, abdominal circumference; FL, femur length; BPD, biparietal diameter; and HC, head circumference 
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Figure 5.2 Correlation between GH2 mRNA concentrations in maternal plasma 
and (A) birth weight, (B) customized birth weight centile, (C) abdominal 
circumference, (D) femur length, (E) biparietal diameter, and (F) head 
circumference. 
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Figure 5.3 Correlation between CSHl, AD AMI 2 mRNA concentrations in 
maternal plasma and (A’E) abdominal circumference, (B，F) femur length, (C，G) 
biparietal diameter, and (D，H) head circumference. 
5.4 Discussion 
Several placental transcripts with function related to fetal or placental growth were 
selected as potential fetal growth markers in Chapter 4. These transcripts had been 
validated to be pregnancy-specific and readily detectable in maternal plasma, 
implicating that they could be developed as markers for noninvasive prenatal 
monitoring. Besides, transcripts that possessed a positive gestational trend 
throughout pregnancy could be potentially related to positive fetal growth along 
gestation. To further evaluate if the selected transcripts could be markers for fetal 
growth monitoring, in this Chapter, various analyses were done to explore the 
relationship between placental circulating mRNA and fetal growth. Analyses were 
performed on pregnancies covering a full range of growth centiles. 
In the first part, I have shown that the absolute expression levels of CSHl, GH2 and 
ADAM 12 mRNA in placental tissues were similar for different fetal weight centiles. 
As the expression of the markers in placental tissues was not affected by birth weight 
centile, any difference in plasma mRNA values could be due to the amount of 
mRNA released into the circulation. For example, it has been reported that the 
placental size bore a positive correlation with birth weight (Thomson et al.’ 1969; 
Molteni et al, 1978; Clapp et al., 1995; Thame et al,, 2004). Since the markers that I 
was evaluating were derived from the placenta (Ng et al., 2003b), I reasoned that 
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their concentrations in maternal plasma might reflect the placental size and/or birth 
weight. Thus, in the second part, I have performed a number of correlation analyses 
to investigate the relationship between maternal plasma levels of the target 
transcripts and several birth measurements and fetal ultrasound growth parameters. 
Interestingly, among the targeted transcripts, plasma GH2 mRNA concentration was 
positively correlated with customized birth weight centile, birth weight and fetal 
ultrasound biometric parameters: AC, FL and BPD. These data suggest that the 
release of GH2 mRNA to maternal plasma may be reflecting fetal growth. 
Correlation between GH2 mRNA in maternal plasma and fetal size was concordant 
with the positive association between serum PGH and birth weight in normal and a 
heterogeneous group of pregnancies including pregnancies suffering from lUGR 
(Caufriez et al.’ 1993; Chellakooty et al., 2002). Ultrasound biometric parameters 
serve as useful indicators for fetal size and thus assessed in routine clinical practice 
for all pregnant women (Ott, 2006). I have demonstrated that plasma GH2 mRNA 
correlated with most fetal ultrasound biometric parameters, including AC, FL and 
BPD, but not HC. HC measures the size of the head and reflects fetal brain growth. It 
is argued that during intrauterine life, the brain grows prior to other organs (Mari et 
al, 1996). Brain growth is promoted by increased blood flow at the expense of the 
circuit that supplies the viscera and muscles. This is apparent in lUGR fetuses. As 
brain development is not much affected by disturbed growth pattern, it is not 
surprising that there is no correlation between HC and GH2 mRNA which had been 
shown to be growth-related. 
The plasma samples used in this Chapter came from various gestational ages of the 
second and third trimesters. It was noted that such gestational age difference may 
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present a potential confounder to the correlation analysis between the maternal 
plasma levels of placental mRNA and fetal growth indicators which have not been 
adjusted for gestational age. In other words, the significant positive correlation 
observed between GH2 mRNA and the several gestational age dependent parameters 
might be confounded by the gestational-related change in marker concentration. To 
eliminate the possible gestation confounding effect, Z-score, also known as standard 
deviate, is sometimes used in statistical analyses. Z-score is calculated based on 
locally-derived nomograms (e.g. fetal biometric chart) that have been determined 
from a cohort of normal singleton livebirth. It is a statistical transformation 
representing how extreme the observation deviates from the median of normal 
pregnancy at a particular gestational age. Using this manipulation, Leung et al. 
showed that first-trimester crown-rump length and PAPP-A are independent factors 
affecting final birth weight (Leung et al., 2006). 
This gestational age issue may confound the data; however, I did not express the fetal 
growth measurements as standardized Z-scores in the analyses. This is because in 
this thesis I aim to introduce a strategy of selecting potential fetal growth markers 
using circulating placental RNA rather than elucidating the mechanism of correlation 
or determining the factors that could influence fetal growth. On the other hand, in 
Chapter 4.3.4，I observed that ADAM 12 mRNA has a stronger gestational trend than 
GH2 mRNA in maternal plasma (2.9-fold and 2.4-fold increase from second to third 
trimester for ADAM 12 and GH2 mRNA, respectively) and yet it did not show any 
correlation with the fetal growth parameters. Moreover, customized birth weight 
centile has taken into account all the well-known epidemiological factors that could 
affect the expected birth size of the baby. Despite its independence of gestational 
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age, GH2 mRNA still significantly correlated with customized birth weight centile. 
Thus, it could be concluded that GH2 mRNA may be a potential fetal growth marker. 
In summary, this Chapter has revealed how circulating placental mRNA 
concentrations may relate to fetal growth by studying the correlation between the 
maternal plasma levels of these transcripts and customized birth weight centile, birth 
and placental weight, and fetal growth parameters estimated by ultrasound scans. 
Notably, GH2 mRNA appeared to be growth-related based on its association with 
customized birth weight centile, birth weight and a number of fetal ultrasound 
measurements. These data have added much value to the possibility of developing 
placental mRNA in maternal plasma as fetal growth markers. 
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CHAPTER 6: Quantitative Analysis of Placental mRNA in lUGR 
with or without PET 
6.1 Introduction 
It is essential but difficult to identify growth restricted fetuses accurately for timely 
intervention (Chauhan et al, 2006). Growth restricted fetuses are at increased risk of 
fetal mortality and morbidity and fetuses surviving from lUGR are still at higher 
susceptibility of poor outcomes in childhood and adulthood (Vrachnis et al.’ 2006). 
One objective means to study the placenta may be by assessing different biochemical 
markers with placental functions. Quantitative analysis of maternal serum protein 
markers in abnormal and normal growth has been extensively studied since the 1950s 
and 1960s (Greene et al.’ 1965). However, these markers perform poorly in terms of 
diagnostic sensitivity (Markestad et al, 1997; Papadopoulou et al., 2000; 
Barkehall-Thomas et al., 2006). Recently, quantitative analysis of fetal nucleic acids 
and lUGR has been focused on fetal DNA analysis which is applicable to male 
fetuses only (Caramelli et al.’ 2003; Sekizawa et al.’ 2003). This thesis studied fetal 
growth from a new approach - the use of circulating placental mRNA. In Chapters 4 
and 5, several highly expressed placental mRNA transcripts detectable in maternal 
plasma (Tsui et al.’ 2004) were targeted as potential fetal growth markers and their 
relationship with fetal growth were investigated. The ultimate goal for developing 
fetal growth markers was to identify lUGR effectively and accurately. 
In this Chapter, I sought to evaluate the possibility of using placenta-derived mRNAs 
in the assessment of growth restricted pregnancies. As discussed in Chapters 4 and 5, 
growth-related transcripts, CSHl, GH2 and ADAM 12 mRNA, were selected as 
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potential fetal growth markers and GH2 mRNA appeared to be reflective to growth 
with positive correlation with birth measurements and ultrasound parameters. Here, I 
hypothesised that the currently assessed growth-related transcripts might be useful in 
identifying lUGR pregnancies. I tested this hypothesis by comparing the absolute 
concentrations of CSHl, GH2 and AD AM 12 mRNA in maternal plasma between 
lUGR associated with or without PET and normal pregnancies. On the other hand, in 
a longitudinal approach, the concentrations of these markers in maternal plasma were 
evaluated throughout pregnancy in both lUGR without PET and normal pregnancies. 
Quantitative analysis of these placenta-derived transcripts could give a better 
understanding of lUGR pathophysiology, as well as the application of this new 
technique for possible future use in prenatal diagnosis and fetal surveillance. 
6.2 Materials and methods 
6.2.1 Sample collection and processing 
Single peripheral blood samples were collected from 31 pregnant women 
complicated with lUGR with or without PET. Serial blood samples were obtained 
from 15 normal and 12 lUGR (without PET) pregnancies. lUGR was defined as 
below 10出 centile of customized birth weight adjusted for maternal height, booking 
weight, parity, sex of baby and gestational age, developed for local Chinese subjects 
(Pang et al.，2000). PET was defined as diastolic blood pressure>110 mmHg on one 
occasion or >90 mmHg on two or more occasions at least 4 hours apart, with the 
presence of significant proteinuria defined as >0.3 g/day in women with no history of 
hypertension (Ng et ai, 2003a). All pregnant women were recruited with informed 
consent from the Prince of Wales Hospital, Hong Kong. Ethical approval was 
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granted by the Joint Chinese University of Hong Kong—New Territories East 
Cluster Clinical Research Ethics Committee. All the samples were processed as 
described in Chapter 3.1. 
6.2.2 Experimental design 
Cross-sectional comparison of placental mRNA concentrations 
To explore the clinical utility of the selected transcripts in the identification of lUGR 
pregnancies, 23 lUGR without PET (gestational age, 30-41 weeks) and 8 lUGR with 
PET (gestational age, 27-35 weeks) were respectively matched with 32 and 13 
normal controls for gestational age and storage duration. In this cross-sectional study, 
I compared the absolute concentration of the selected transcripts in the plasma of 
pregnancies complicated with lUGR with or without PET and normal controls. 
Longitudinally comparison of placental mRNA concentrations 
On the other hand, the effect of lUGR on the concentrations of potential fetal growth 
markers in maternal plasma was studied longitudinally through a range of gestational 
ages. I obtained 2-5 serial blood samples (gestation age, 16-38 week) from 12 lUGR 
without PET and 7 normal pregnancies. The plasma levels of the selected transcripts 
along gestation were compared between lUGR without PET and normal controls. 
6.2.3 RNA extraction and quantification 
Total RNA was extracted from plasma with the protocol illustrated in Chapter 3.2.1. 
All target transcripts were quantified using one-step QRT-PCR as described in 
Chapter 3.3.2. Negative genomic DNA contamination was confirmed for the GH2 
non-intron spanning assay as suggested in Chapter 3.3.3. 
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6.2.4 Statistical analysis 
For the cross-sectional study, the lUGR cases were compared with normal controls 
matched for gestation age. Statistical analysis was performed by the logistic 
regression software LogXact 8 (Cytel) which features matched case-control 
comparison for small sample size. For the longitudinal study, as the number of serial 
samples per case was different, MLwIN 2.0 (CMM) was chosen for multilevel 
statistical analysis which adjusts for unbalanced data in repeated measurements 
(Rasbash, 2004). 
6.3 Results 
6.3.1 Cross-sectional comparison of placental mRNA concentrations 
In order to evaluate the clinical utility of the potential fetal growth markers in the 
identification of lUGR, I have conducted a cross-sectional comparison of the 
placental mRNA concentrations between lUGR with or without lUGR and normal 
pregnancies. 23 lUGR without PET (gestational age, 30-41 weeks) and 8 lUGR with 
PET (gestational age, 27-35 weeks) were respectively matched with 32 and 13 
normal controls for gestational age and storage duration. I compared the absolute 
concentration of CSHl, GH2 and AD AM 12 in the plasma of pregnancies complicated 
with lUGR with or without PET and normal controls. The median AD AM 12 mRNA 
concentrations in maternal plasma was 701 copies/mL (IQR, 311-1586) and 96 
copies/mL (IQR, 55-451) in the lUGR with PET and normal control groups, 
respectively. The difference was equivalent to a 7.3-fold elevation of maternal 
plasma ADAM 12 mRNA concentration in the lUGR with PET group relative to the 
control group (Figure 6.IF) that has reached statistically significant difference 
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(LogXact logistic regression by matched case-control analysis, P = 0.01337). On the 
contrary, there was no significant difference in the absolute maternal plasma 
concentrations of all transcripts between lUGR without PET and control groups 
(Figure 6.1A-C), as well as maternal plasma CSHl and GH2 mRNA between lUGR 
with PET and control groups (Figure 6.1D-E) (LogXact logistic regression by 
matched case-control analysis, P > 0.05 for all comparisons and transcripts). 
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Figure 6.1 Box plots o f (A) CSHl m R N A (B) GH2 m R N A , and (C) ADAM12 
mRNA concentrations in maternal plasma of lUGR and normal control groups; and 
(D) CSHl mRNA (E) GH2 mRNA, and (F) ADAM 12 mRNA concentrations in 
maternal plasma of lUGR with PET and normal control groups. The lines inside the 
boxes denote the medians. The boxes mark the intervals between the and 
percentiles. The whiskers denote the intervals between the and percentiles. • 
indicates a data point outside the and percentiles. 
6.3.2 Longitudinal comparison of placental mRNA concentrations 
In another approach, the effect of lUGR on the concentration of the selected 
transcripts in maternal plasma was examined in a longitudinal study. I collected 
serial blood samples (gestation age, 16-38 wk) from 12 lUGR without PET and 7 
normal pregnancies and monitored the concentrations of CSHl, GH2 and ADAM 12 
mRNA through a range of gestational ages. Because of the inconsistent number of 
serial blood samples collected from different subjects, multilevel statistics was 
chosen to study the effect of lUGR on repeated measurements. In the multilevel 
model, repeat plasma RNA measurements within the same subject at different time 
points belong to the first level and the different subjects belong to the second level. 
No significant difference was seen for all transcripts between the lUGR and normal 
groups after adjustment for gestational age effect (MLwiN multilevel analysis of 
repeated measures data, P > 0.05 for all transcripts). 
Taken together, it is suggested that there was aberrant concentration of maternal 
plasma AD AM 12 mRNA only when lUGR was complicated with PET. Both the 
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cross-sectional and longitudinal studies revealed no significant difference between 
the concentrations of CSHl, GH2 and ADAM 12 mRNA in maternal plasma between 
lUGR alone relative to normal pregnancies. 
6.4 Discussion 
Driven by the interesting finding that one of the selected potential fetal growth 
markers, GH2 mRNA, appeared to be reflective of growth with significant 
correlations with several fetal growth parameters, birth weight and customized birth 
weight centile as demonstrated in Chapter 5,1 hypothesized that such growth-related 
placental mRNA species could be useful in the prenatal identification of lUGR 
pregnancies. In this Chapter, the clinical utility of the selected potential fetal growth 
markers was explored for the prenatal assessment of lUGR. At present, there are no 
ideal consensus definitions or standards for the diagnosis of lUGR (Bakketeig, 1998; 
Maulik, 2006). In this study, lUGR was defined with the local customized birth 
weight centiles which is adjusted for maternal height, booking weight, parity, sex of 
baby and gestational age (Pang et al” 2000). The performance of the customized 
birth weight centile was evaluated and it has been shown to give improved 
differentiation between normal and abnormal growth than the commonly used 
population-based birth weight centiles (Pang et al, 2000). This aids in excluding 
those constitutionally small fetuses and including those larger size fetuses that were 
missed out with the population standard. 
To examine if the selected placental transcripts could be applied to differentiating 
lUGR from normally growing fetuses, I have studied if they were associated with 
aberrant concentrations by two approaches: cross-sectional comparison and 
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longitudinal comparison of the maternal plasma concentrations of these markers in 
fetal growth restricted or normal pregnancies. First of all, in the cross-sectional 
study, the absolute concentrations of maternal plasma CSHl’ GH2 and ADAMl2 
were compared between lUGR with or without PET and normal singleton 
pregnancies. No significant difference was observed except for ADAM 12 mRNA, 
where significantly higher concentrations were seen in lUGR with PET when 
compared to the normal group. Next, I also studied pregnancies with lUGR but not 
PET and compared their serial plasma concentrations of the targeted transcripts with 
those of normal controls. No significant difference could be seen, which was 
comparable to the absolute quantification data. Collectively, these data suggested 
that there was no aberrant concentration of our target growth markers in pregnancies 
with lUGR only. Indeed, previous studies involving similar number of subjects 
showed no significant difference in maternal plasma fetal DNA concentration for 
lUGR (Sekizawa et al, 2003) but higher concentrations in lUGR pregnancies with 
abnormal uterine artery Doppler waveforms and at risk for PET (Caramelli et al.’ 
2003). Recently, a study shows no increase of fetal DNA before 20 weeks of 
pregnancy in lUGR (Crowley et al.’ 2007). 
The increased release of ADAM12 mRNA into the plasma of lUGR with PET 
pregnant women may be related to increased placental ADAM 12 mRNA expression 
in preeclamptic placental tissue which is in agreement with previous studies on 
ADAM 12 at the protein level (Gack et al, 2005). Moreover, increased 
concentrations of cell-free nucleic acids in PET has been reported in several studies 
(Lo et al,’ 1999b; Zhong et al.’ 2001b; Ng et al.’ 2003a; Levine et al.’ 2004; 
Sekizawa et al, 2008) and speculated to be associated with increased placental 
apoptosis in pregnancies complicated by PET (DiFederico et al, 1999; Leung et al” 
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2001a). Since there was no significant difference of AD AM 12 mRNA in lUGR alone 
versus normal controls, it would be worthwhile to investigate in future studies 
whether the same extent of AD AM 12 mRNA elevation as observed in lUGR with 
PET pregnancies could be found in PET alone (without lUGR). By doing so, we 
could decide if the elevation observed in this study was due to PET only or the 
cumulative detrimental effects of both lUGR and PET. 
It was demonstrated in Chapter 5 that GH2 mRNA in maternal plasma showed 
correlations for fetal size, which suggested that this transcript might be useful in 
identifying small fetuses. However, as shown in both the cross-sectional and 
longitudinal quantitative analyses, maternal plasma GH2 mRNA could not 
discriminate lUGR from normal pregnancies. This could be due to the following 
reasons. The role of GH2 in the pathophysiology of lUGR remains to be elucidated. 
Despite reports of decreased levels of serum placental growth hormone in 
pregnancies complicated with lUGR (Caufriez et al.’ 1993; Mclntyre et al., 2000), 
controversy exists in the expression of GH2 mRNA in the lUGR placenta (Chowen 
et al, 1996; Sheikh et al., 2001). One study illustrated a decreased mean number of 
cells per placental area expressing GH2 mRNA in lUGR, whereas the mean GH2 
mRNA level per cell did not differ between normal and lUGR placentas (Chowen et 
al.’ 1996). In contrast, another study of larger sample size demonstrated increased 
expression of GH2 mRNA in lUGR placentas at term (Sheikh et al, 2001). In 
addition, the pathogenesis of lUGR is multifactorial, including a variety of risk 
factors originating from the mother, fetus, placenta and environment (Bryan and 
Hindmarsh, 2006). During the diagnosis of lUGR, it is always hard for obstetricians 
to identify the underlying cause(s). The recruited lUGR cases for this study may each 
be due to different etiology, which may have different effect to the detected amount 
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of GH2 mRNA in maternal plasma. Thus, despite statistically significant correlation 
between various fetal growth measurements and GH2 mRNA plasma concentrations 
as shown in Chapter 5, GH2 mRNA might not be sensitive enough to identify lUGR 
fetuses in our analyzed cohort of lUGR cases potentially with mixed etiology. The 
value of GH2 mRNA measurement for lUGR pregnancies would need to be further 
investigated in larger cohorts of controls and cases, preferably in sub-groups with 
better defined etiologies. 
In this Chapter, I have explored the clinical application of circulating placental 
mRNA in maternal plasma as markers for lUGR by cross-sectional and longitudinal 
analyses. lUGR with PET pregnancies were associated with aberrantly higher 
concentration of maternal plasma ADAM 12 mRNA, implicating that AD AM 12 
mRNA may be useful to identify lUGR complicated with PET. There was no 
significant difference between lUGR alone and normal pregnancies. The clinical 
utility of the currently assessed markers could be explored in future studies as 
suggested in Chapter 7.3. 
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CHAPTER 7: Conclusion and Future Perspectives 
7.1 A strategy for identifying circulating placental mRNA markers for fetal 
growth assessment 
Monitoring and assessment of fetal growth form a fundamental part of prenatal care. 
Abnormal fetal growth, particularly lUGR, is a serious obstetric problem that is 
associated with poor outcomes at all stages of life (Vrachnis et al.’ 2006). Research 
on fetal growth monitoring has long been focused on the development of an objective 
means to identify disturbed in utero growth patterns. In order to explore a new 
avenue for fetal growth assessment, this thesis aims to study the quantitative 
relationship between circulating placental mRNA and fetal growth. The discovery of 
placenta-derived fetal RNA in maternal plasma has opened up new research 
opportunities for noninvasive prenatal investigation (Ng et al., 2003b). Not only it 
could potentially be applied to all pregnancies without the limitations of fetal gender 
and polymorphisms between the mother and the fetus, but also provide valuable 
information regarding the gene expression profile of the fetus (Tsui et al., 2004) 
which would be altered by placental dysfunction (Ng et al., 2003a). 
The strategy for searching potential fetal growth markers has been based on targeting 
fetal/placental growth-related placental transcripts that were previously identified by 
microarray analysis (Chapter 4). Since the profile of circulating placenta-derived 
mRNA is reflective of placental tissue gene expression, it was postulated that the 
maternal plasma concentrations of the selected growth-related transcripts would 
mirror placental function and enable indirect monitoring of fetal growth. In Chapter 
4, CSHl, GH2, KISSl and ADAM�2 were identified using this approach. They could 
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be quantified by real-time QRT-PCR assays, and were validated to be 
pregnancy-specific and readily detectable in maternal plasma at different stages of 
gestation. Via the cohort group comparison and serial monitoring of the plasma 
levels of these transcripts throughout pregnancy, CSHl, GH2 and ADAM 12 mRNA 
displayed a gradual increasing trend as gestation progressed, whereas similar level 
was demonstrated for KISSl mRNA. Predictably, growth-related transcripts should 
possess an increasing gestational trend along with positive fetal growth; therefore, 
KISSl mRNA was excluded as being one of the candidates of potential growth 
markers. 
In order to establish circulating placental mRNA as possible fetal growth markers, it 
is important to know how they were related to fetal growth. This relationship was 
studied by correlation analyses between such RNA species and several fetal growth 
indicators, including customized birth weight centile, birth/placental weight and fetal 
biometric measurements estimated by ultrasound scans (Chapter 5). It was expected 
that since the placental size positively correlated with birth weight (Thomson et al.’ 
1969; Molteni et al., 1978; Clapp et al., 1995; Thame et al., 2004), the currently 
assessed growth-related placental transcripts would potentially reflect the placental 
size and/or birth weight. Remarkably, GH2 mRNA in maternal plasma significantly 
correlated with birth weight and a number of fetal growth parameters, which is 
concordant with results obtained at its protein level (Caufriez et al., 1993; 
Chellakooty et al., 2002). These data suggest that the release of GH2 mRNA to 
maternal plasma may be reflecting fetal growth. 
Prompted by the interesting relationship between circulating placental mRNA, the 
clinical utility of the targeted fetal RNA species to differentiate normal and growth 
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restricted fetuses was explored (Chapter 6). Aberrantly higher concentrations of 
ADAM 12 mRNA in maternal plasma could be found in pregnancies of lUGR 
associated with PET relative to gestational age-matched normal control. This has 
been speculated to be due to increased expression of ADAM 12 in preeclamptic 
pregnant women at both the placental tissue and serum level (Gack et al.’ 2005), and 
increased placental apoptosis in pregnancies complicated by PET (DiFederico et al., 
1999; Leung et al., 2001a). It was noted that no significant difference of the target 
transcripts in maternal plasma could be seen between lUGR alone and normal 
pregnancies in both cross-sectional and longitudinal analyses (Chapter 6). Indeed, 
this is in agreement with previous studies on circulating fetal DNA and lUGR 
(Caramelli et al., 2003; Sekizawa et al, 2003). Sekizawa et al. showed that there was 
no difference in fetal DNA in the plasma of pregnant women with and without fetal 
growth restriction (Sekizawa et al, 2003), whereas Caramelli et al. reported 
increased fetal DNA in lUGR pregnancies at risk of PET (Caramelli et al.’ 2003). 
It may be disappointing as GH2 mRNA appeared most likely to be growth-related 
among the target transcripts (Chapter 5)，but it was not useful in the clinical 
assessment of lUGR. This could be attributed to the weak though significant 
correlation between the various fetal growth measurements and the maternal plasma 
concentrations of GH2 mRNA. Moreover, to date, the role of GH2 in the 
pathophysiology of lUGR was still poorly understood and proposed by controversial 
arguments (Chowen et al., 1996; Sheikh et al, 2001). Even so, the clinical utility of 
the currently assessed markers could be studied in further large-scale studies. It is 
anticipated that good markers for fetal growth assessment using circulating placental 
mRNA would be developed subsequently. 
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In summary, this thesis has developed and demonstrated a new strategy in 
identifying surrogate markers for the study of fetal growth or the pathophysiolgy of 
lUGR. I have provided fundamental information on the relationship between 
placental mRNA in maternal plasma and fetal growth and lUGR. The work from this 
thesis examined the possibility of circulating fetal RNA in fetal growth assessment, 
thus expanding the application of fetal RNA in noninvasive prenatal monitoring. It 
has also opened up the possibility that a similar approach can be used to identify 
maternal plasma RNA markers for other obstetric conditions involving placental 
dysfunction. 
7.2 Implications of mRNA marker development strategy 
This thesis described a potential strategy for searching for fetal growth markers from 
a panel of placental transcripts generated by microarray approach (Tsui et al., 2004) 
by targeting genes that were functionally linked to fetal/placental development and 
also highly expressed in the placenta. In fact, based on the same microarray 
experiment, a recent study discovered a novel fetal RNA marker in maternal plasma 
for the detection of T21 noninvasively (Lo et al.’ 2007b). This was achieved by 
targeting the most highly expressed placental transcript located on chromosome 21 
gene, namely placenta-specific 4 (PLAC4). By determining the allelic ratio of such a 
single marker, sensitivity of 90% and specificity of 96% have been achieved for 
noninvasive prenatal chromosomal aneuploidy detection (Lo et al.，2007b). Both this 
study and the current thesis have validated the potential use of previously reported 
microarray investigation of placental tissue for fetal RNA marker development (Tsui 
et al, 2004). 
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Circulating placental mRNA markers provide several advantages for screening of 
pregnancy-related diseases. Despite various maternal serum protein markers 
revealing altered levels in many placental disorders, they lack discriminative and 
predictive value (Markestad et al.’ 1997; Barkehall-Thomas et al.’ 2006). On the 
contrary, multiple placental RNA markers can be easily extracted and analyzed at 
one time which allows rapid screening of a panel of novel fetal markers even for 
RNA species not accessible by immunoassays (Juan et al., 2000). This will be much 
less labor-intensive and time-consuming when compared to protein immunoassays. 
Potential problems like crossreactivity (Klee, 2004) of the antibodies used in protein 
assays can be avoided as the RNA quantification assay only requires a set of specific 
primer pair and probe. 
7.3 Prospects for future work 
Research on fetal growth has been so challenging because of the complexity and 
dynamic nature of fetal growth physiology, the multifactorial pathogenesis of lUGR 
and the lack of consensus on definition of inadequate fetal growth. There is a 
longstanding quest for an objective means for fetal growth assessment. The results 
presented in this thesis have not only opened up the field of considering placental 
mRNA in maternal plasma to serve as fetal growth markers, but also introduced a 
novel strategy to search for surrogate markers in fetal growth or lUGR assessment. 
Being the first study to address the potential use of placental mRNA in maternal 
plasma in the study of fetal growth, this has laid the ground for prospective studies of 
this new field in assessing growth or using the presented strategy to search for novel 
markers. 
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Firstly, it would be useful to establish normal reference ranges of the currently 
assessed markers so that their concentrations in maternal plasma could be compared 
based on multiples of median (MoM) assessments independent of gestational age. 
Gestational trends have been illustrated in Chapter 4 for potential fetal growth 
mRNA markers. Previous studies have also shown similar gestation-related 
variations in other placental transcripts (Ng et al., 2003b; Farina et al, 2004). As 
discussed in Chapter 5, gestational age may be a potential confounder to the analyses 
of marker concentrations with gestation-related trends. By recruiting a large cohort 
of reference normal pregnancies for various gestational periods, gestation-specific 
reference intervals can be established for concentrations of the selected fetal growth 
transcripts in maternal plasma. The median maternal plasma RNA concentrations 
could be determined for each gestational interval and normality for the data spread 
within each gestation could also be assessed (Farina et al., 2004). 
Secondly, a previous study showed no correlation between the concentration of 
maternal plasma fetal DNA and placental size during the first trimester (Wataganara 
et al., 2005), which could be due to differences in the release mechanism of fetal 
DNA and RNA. The amount of plasma fetal RNA is also influenced by the gene 
expression profile (Tsui et al.，2004) besides being governed by the rate of placental 
apoptosis (Tjoa et al.’ 2006a) which is the main factor regulating the amount of 
plasma fetal DNA. Therefore, it would be worthwhile to compare the placental 
volume measured by 3-dimensional ultrasound (Wataganara et al.’ 2005) at different 
gestational ages with the respective plasma RNA levels of the growth markers. This 
would provide a better understanding on how placental RNA in maternal plasma 
varies relative to placental or fetal size throughout pregnancy. 
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Thirdly, the clinical utility of the currently assessed markers could be further 
explored in larger-scale studies with more frequent follow-up for ultrasound 
scanning and blood collection at better synchronized gestational-age time points 
between subjects. In the present study, the serial samples of the lUGR and control 
cases were collected at different gestational age and time intervals (Chapter 6). With 
the synchronized time-points, the rate of change of growth parameters could be 
compared with the rate of change of maternal plasma RNA. The Z-score of the 
biometric measurements could be compared to the MoM values of the plasma marker 
(Sorensen et al., 2000; Leung et al.’ 2008). 
Fourthly, Chapter 6 revealed significant dilTerence of ADAM 12 mRNA in lUGR 
associated with PET only, but not lUGR alone, versus normal controls. In future 
studies, the relationship between ADAM 12 mRNA and PET alone could be 
investigated in order to elucidate if AD AM 12 elevation observed in this thesis was 
solely due to PET or the cumulative detrimental effects of both lUGR and PET. 
Aside from PET, ADAM 12 is also suggested for Down syndrome and T18 screening 
(Laigaard et al, 2003; Laigaard et al., 2005). It is also possible to explore if aberrant 
AD AM 12 mRNA in maternal plasma is associated with fetal aneuploidies. 
Lastly, the potential marker-search strategy that 1 have developed here may be useful 
in studying other obstetric conditions iliat involves placental dysfunction. For 
example, placental genes that have been shown to be related to the pathophysiology 
of PET, such as inhibin A and leptin (My a it, 2002), are also present in the microarray 
gene list. 
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This thesis has highlighted a potential strategy that enabled the development of 
maternal plasma fetal growth mRNA markers. With further elucidation of the 
relationship between such markers and fetal growth or lUGR, it is envisioned that 
circulating placental mRNA could play an important role in the monitoring of fetal 
growth. Moreover, it is also anticipated that the application of this strategy for 
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